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Abstract: Neurotropic viruses infect the central nervous system (CNS) and cause acute or chronic
neurologic disabilities. Regulatory T cells (Treg) play a critical role for immune homeostasis, but may
inhibit pathogen-specific immunity in infectious disorders. The present review summarizes the
current knowledge about Treg in human CNS infections and their animal models. Besides dampening
pathogen-induced immunopathology, Treg have the ability to facilitate protective responses by
supporting effector T cell trafficking to the infection site and the development of resident memory T
cells. Moreover, Treg can reduce virus replication by inducing apoptosis of infected macrophages and
attenuate neurotoxic astrogliosis and pro-inflammatory microglial responses. By contrast, detrimental
effects of Treg are caused by suppression of antiviral immunity, allowing for virus persistence and
latency. Opposing disease outcomes following Treg manipulation in different models might be
attributed to differences in technique and timing of intervention, infection route, genetic background,
and the host’s age. In addition, mouse models of virus-induced demyelination revealed that Treg
are able to reduce autoimmunity and immune-mediated CNS damage in a disease phase-dependent
manner. Understanding the unique properties of Treg and their complex interplay with effector
cells represents a prerequisite for the development of new therapeutic approaches in neurotropic
virus infections.
Keywords: regulatory T cells; Foxp3; central nervous system; neurotropic viruses; neuroinflammation;
animal models; demyelination
1. Introduction
A variety of viruses are able to infect the central nervous system (CNS) and contribute to neurologic
diseases in humans and animals worldwide. Although most viral infections are self-limiting and
asymptomatic in immunocompetent hosts, some neurotropic viruses can cause acute and fatal or
severely debilitating inflammation. Moreover, virus persistence or long-term neurologic disabilities,
as well as an increased risk of developing epilepsy, can be observed in patients surviving acute viral
encephalitis [1–3]. CNS lesion development and disease outcome depends on host factors (e.g., age,
gender, immunogenetics) and viral properties. Virus infection of the CNS typically leads to lymphocytic
inflammation, glial activation, and tissue damage, including necrosis and demyelination (Table 1).
Besides direct virus-induced cytopathology, several neurologic disorders are caused by excessive
antiviral immune responses [3]. Certain pathogens, including herpesviruses, are also suspected triggers
of autoimmune diseases, such as multiple sclerosis (MS), anti-N-methyl-D-aspartate (NMDA) receptor
encephalitis, or Guillain.
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Table 1. Pathology of selected human virus infections of the central nervous system.
Group Virus Family Virus Name Disease Name Pathologic Findings in the Central Nervous System (GrossFindings; Histologic Findings) References
RNA viruses
Flaviviridae
Zika virus Congenital Zikasyndrome
Microcephaly, ventriculomegaly; mononuclear infiltrates, gliosis,
calcification, neuronal necrosis [4–8]
West Nile virus West Nile encephalitis Mononuclear infiltrates, gliosis, neuronal necrosis, neuronophagia,occasionally demyelination [9]
Japanese encephalitis
virus Japanese encephalitis
Cerebral congestion and edema; mononuclear infiltrates, gliosis,
necrosis, hemorrhages, neuronophagia [10]
Retroviridae
Human
immuno-deficiency
virus (HIV)
HIV encephalitis Mononuclear infiltrates, multinucleated giant cells, gliosis, neuronalloss, spongy myelinopathy, demyelination, vascular damage [11]
Orthomyxoviridae Influenza virus Influenza-associatedacute encephalopathy
Cerebral edema and hemorrhage; neuronal apoptosis, necrosis, gliosis,
occasionally mononuclear infiltrates [12–14]
Paramyxoviridae
Measles virus
Measles inclusion
body encephalitis
Gliosis, intranuclear and cytoplasmic inclusion bodies in neurons and
glial cells, mild mononuclear infiltration [15–17]
Subacute sclerosing
panencephalitis
Cortical atrophy; mononuclear infiltrates, gliosis, neuronal necrosis
and neuronophagia, intranuclear inclusion bodies (Cowdry type A) in
neurons and oligodendrocytes, demyelination
[15–17]
Nipah virus, Hendra
virus
Henipavirus
encephalitis
Mononuclear infiltrates, vasculitis and thrombosis with infarctions,
neuronophagia, gliosis, endothelial syncytia with inclusion bodies [18]
Mumps virus Mumps encephalitis Mononuclear infiltrates, demyelination, gliosis, neuronal degeneration,hemorrhage, hyaline thrombi [19]
Rhabdoviridae Rabies virus Rabies Mononuclear infiltrates, gliosis, neuronal necrosis, neuronophagia,cytoplasmic inclusion bodies (Negri bodies) in neurons [20]
Bornaviridae Variegated squirrel 1bornavirus
Borna virus-associated
encephalitis
Mononuclear infiltrates, gliosis, edema, necrosis, neuronal necrosis,
neuronophagia [21,22]
Togaviridae Eastern equineencephalitis virus
Eastern equine
encephalitis
Mononuclear infiltrates, gliosis, infarcts with hemorrhages, myelin
pallor and Purkinje cell loss in cerebellum [23]
Bunyaviridae La Crosse virus La Crosse encephalitis Mononuclear infiltrates, gliosis [24]
DNA viruses Herpesviridae
Herpes simplex virus Herpes simplexencephalitis
Mononuclear infiltrates, hemorrhages, necrosis, intranuclear inclusion
bodies (Cowdry type A) in neurons and glial cells [25]
Epstein–Barr virus
(EBV)
EBV-associated
encephalitis/vasculitis
Mononuclear infiltrates, vascular fibrinoid necrosis, hemorrhage,
occasionally demyelination [26–28]
Varicella-zoster virus
(VZV) VZV encephalitis
Vasculopathy, vascular fibrinoid necrosis and thrombosis, necrosis,
hemorrhagic infarcts, demyelination, intranuclear inclusion bodies
(Cowdry type A) in glial and ependymal cells
[29,30]
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Barré syndrome occurs in predisposed individuals [31,32]. Thus, despite the need for protection
against viral invasion and replication, the extent of the immune response in the CNS needs to be carefully
regulated to prevent bystander tissue damage and immunopathology. Regulatory T cells (Treg), a cluster
of differentiation (CD)4+ T cell subset with immunosuppressive and immunomodulatory functions,
are principle regulators of immune reactions and mediators of peripheral tolerance. They contribute to
tissue homeostasis under steady state conditions and regulate immune responses in inflammatory
diseases [33,34]. Immunomodulation represents a promising new application for treating autoimmune
and infectious diseases, including neurologic disorders. Mechanisms to enhance regulatory T cell
function in order to prevent pathogen-induced, immune-mediated tissue damage as well as approaches
to reduce their function to strengthen protective immunity and vaccination immunogenicity have
been proposed [35–37]. The present review summarizes the current knowledge on Treg involvement
in human CNS infections and the effects of Treg manipulation in experimental models of human
neutrotropic virus infection and virus-induced demyelination.
2. Biology of Regulatory T cells
Prevention of immunopathology in the course of inflammation and maintenance of self-tolerance
requires mechanisms that dampen deleterious immune responses. Several cell types with regulatory
functions have been described, including CD4+CD25+forkhead box protein P3 (Foxp3)+ regulatory
T cells (Treg), type 1 regulatory T cells (Tr1 cells), invariant natural killer T cells, double negative
CD3+ helper cells, γδ-T cells, CD8+Foxp3+ T cells, regulatory B cells, and myeloid suppressor cells.
Among them, Treg are the most-studied and well-characterized cell type, and their paramount
importance for immune homeostasis has been amply demonstrated [38–41]. Defects in the gene
coding for the Treg-specific transcription factor forkhead box protein P3 (Foxp3) lead to an aggressive
and fatal autoimmune disorder known as immune dysregulation, polyendocrinopathy, enteropathy,
X-linked syndrome (IPEX) in humans and a comparable systemic lymphoproliferative disease in
scurfy mutant mice [42,43]. Besides their role in peripheral tolerance to the self, Treg are also involved
in the suppression of excessive immune responses evoked by commensal microbiota and invading
pathogens [44,45]. There are two main types of Treg: natural Treg (nTreg) are generated in the
thymus, whereas induced Treg (iTreg) arise de novo from naïve CD4+ T cells in the periphery upon
Foxp3 induction mediated by interleukin (IL)-2 and transforming growth factor (TGF)-β signaling
(Figure 1a) [46,47]. Treg exert inhibitory functions on a variety of immune cells, including T and B cells,
natural killer cells, and cells of the innate immune system via cell contact-dependent and -independent
mechanisms (Figure 1b). For instance, Treg show a high expression of cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4), which competes with CD28 for the co-stimulatory molecules B7-1 and B7-2 on
antigen-presenting cells and thereby prevents T cell priming. Treg require IL-2 derived from other cell
sources as a growth and survival factor and constitutively express CD25, which is a part of high affinity
IL-2 receptors [48–50]. Owing to that, they can deprive other T cells of IL-2, which suppresses their
activation and effector function [51]. Interestingly, although Treg restrict the population of CD8+ effector
T cells, they promote the formation of memory T cells in viral infections of the CNS (see below). The most
important Treg-secreted soluble mediators are the anti-inflammatory cytokines IL-10, IL-35, and TGF-β,
which can induce a plethora of immunomodulatory downstream effects on a variety of responsive cell
types. Treg also express the ectoenzymes ATP apyrase (CD39) and ecto-5′-adenosine monophosphate
(AMP)-nucleotidase (CD73), which generate the immunosuppressive purine nucleoside adenosine.
Moreover, Treg are capable of directly killing syngeneic cells such as T cells, monocytes, and dendritic
cells through granzyme/perforin and caspase-3-involving pathways [52–55]. This ability is not only
important for the limitation of overwhelming immune responses but can also facilitate virus elimination
through the execution of infected macrophages, as was shown in the murine human immuno-deficiency
virus (HIV)-encephalitis model (see below). Moreover, there is cumulating evidence that distinct
subtypes of Treg exist in certain tissue environments (e.g., skin and CNS) and that Treg in those
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niches might be equipped with additional, site-specific effector functions and induce responses beyond
immune regulation [56,57].
Treg function in inflammatory disorders is commonly investigated by depletion/inactivation or
increase of Treg numbers in mice. To that end, two types of transgenic knock-in mice were developed,
which express the human or simian diphtheria toxin receptor (DTR) under control of the Foxp3
promoter and allow a specific Treg depletion upon DT injection (Foxp3DTR or depletion of regulatory T
cells (DEREG) mice) [58,59]. Moreover, functional inactivation of Treg is possible using antibodies
directed against CD25 (clone PC61) [60]. Enhancement of Treg responses is achieved by adoptive
transfer of Treg or by expansion of endogenous Treg using IL-2 immune complexes (IL-2C, consisting
of recombinant IL-2 and anti-IL-2-antibodies, clone JES6-1), which selectively expand cells expressing
CD25 [34,61,62]. The approaches targeting CD25 have the disadvantage of simultaneous inactivation
or expansion of other cells transiently expressing CD25 (e.g. activated T cells) [61,63], whereas Foxp3
is highly specific for the Treg population.
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Figure 1. Types and functions of regulatory T cells (Treg). (a) There are two main types of Treg in 
humans and mice. Natural Treg (nTreg) are generated in the thymus from precursor T cells 
recognizing self-antigens presented by thymic antigen presenting cells (APC) via major 
histocompatibility complex (MHC) II molecules. The differentiation to the Treg phenotype is further 
influenced by local cytokines. nTreg express high levels of Helios and neuropilin-1 (Nrp1). Treg can 
also be generated de novo from naïve conventional cluster of differentiation (CD)4+ T cells in 
extrathymic tissues in the presence of interleukin (IL)-2, transforming growth factor (TGF)-β, and 
retinoic acid following T cell receptor (TCR) engagement. These induced Treg (iTreg) express low 
levels of Helios and Nrp1. Both Treg types are characterized by the expression of the transcription 
factor forkhead box protein P3 (Foxp3) and CD25. (b) Treg exert their suppressive function by various 
cell contact-dependent and -independent mechanisms. These include cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4)-dependant suppression of B7-mediated co-stimulation of conventional 
T cells (Tconv), Lymphocyte activation gene 3 (LAG-3)-mediated suppression of dendritic cell 
(DC) maturation, IL-2 deprivation of other T cells through expression of high-affinity IL-2 receptors 
(IL2R), and generation of the immunosuppressive nucleotide adenosine by the ectoenzymes CD39 
and CD73. Moreover, Treg secrete the anti-inflammatory cytokines IL-10, TGF-β, and IL-35, and 
induce apoptosis of inflammatory cells through granzyme/perforin secretion. Treg also shift 
macrophage polarization from M1 to the M2 type and induce the activity of the immunosuppressive 
enzyme indoleamine 2,3-dioxygenase (IDO) in DCs. 
 
Figure 1. Types and functions of regulatory T cells (Treg). (a) There are two main types of
Treg in humans and mice. Natural Treg (nTreg) are generated in the thymus from precursor
T cells recognizing self-antigens presented by thymic antigen presenting cells (APC) via major
histocompatibility complex (MHC) II molecules. The differentiation to the Treg phenotype is further
influenced by local cytokines. nTreg express high levels of Helios and neuropilin-1 (Nrp1). Treg
can also be generated de novo from naïve conventional cluster of differentiation (CD)4+ T cells in
extrathymic tissues in the presence of interleukin (IL)-2, transforming growth factor (TGF)-β, and
retinoic acid following T cell receptor (TCR) engagement. These induced Treg (iTreg) express low levels
of Helios and Nrp1. Both Treg types are characterized by the expression of the transcription factor
forkhead box protein P3 (Foxp3) and CD25. (b) Treg exert t ir suppressive fun tion by various cell
contact-dependent and -independent mechanisms. These include cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4)-dependant suppression of B7-mediated co-stimulation of conventional T cells
(Tconv), Lymphocyte activation gene 3 (LAG-3)-mediated suppression of dendritic cell (DC) maturation,
IL-2 deprivation of other T cells through expression of high-affinity IL-2 receptors (IL2R), and generation
of the immunosuppressive nucleotide adenosine by the ectoenzymes CD39 and CD73. Moreover, Treg
secrete the anti-inflammatory cytokines IL-10, TGF-β, and IL-35, and induce apoptosis of inflammatory
cells through granzyme/perforin secretion. Treg also shift macrophage polarization from M1 to the M2
type and induce the activity of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO)
in DCs.
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3. Regulatory T Cells in Neuroinflammation and Neuroprotection
Treg play a critical role for immune homeostasis and prevent immunopathology in the brain
and spinal cord though interaction with infiltrating immune cells and resident CNS cells (Figure 2).
The beneficial impact of Treg functions in the context of autoimmune CNS disorders has been
extensively studied in experimental autoimmune encephalomyelitis (EAE), an animal model for human
MS. Treg have been shown to suppress encephalitogenic T cells, resulting in sustained self-tolerance [64].
Besides exerting modulatory effects in peripheral lymphoid organs, infiltrating Treg directly influence
the local inflammatory milieu in the CNS [65,66]. The choroid plexus is thought to favor the entrance
of Treg and T helper (Th)17 cells, whereas the blood–brain barrier may favor the CNS recruitment of
Th1 cells and memory T cells [67]. Chemokine ligands (CCL)1 and CCL20 produced by astrocytes and
oligodendrocytes initially attract Treg, as shown in ischemic brains [33]. Moreover, CCL22 secretion by
activated microglia leads to an enhanced CNS migration of Treg [68,69]. Recently, a distinct cerebral
Treg population has been described, which differs from peripheral Treg in the gene expression pattern.
Brain Treg express the transcription factor Helios, killer cell lectin-like receptor subfamily G member 1
(KLRG1), and the serotonin receptor 7, as well as high levels of CTLA-4, ST2 (IL-33 receptor subunit),
and programmed cell death-1 (PD-1) [33]. It remains undetermined whether these Treg are locally
instructed within the brain to adopt tissue-specific properties or whether specific subsets of Treg are
selectively recruited to the CNS [57,58]. Treg-expansion in the CNS is driven by IL-2, the alarmin IL-33,
and the neurotransmitter serotonin. IL-33 and serotonin are constitutively expressed in the CNS and
are able to substitute the role of IL-2 in mediating Treg survival and maintenance, for example under
post-inflammatory conditions [33].
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(AREG) and cytokines, as well as through cell contact-dependent mechanisms. Moreover, Treg are 
involved in CNS regeneration: Treg-derived cellular network communication factor 3 (CCN3) 
promotes (re)myelination and differentiation of mature oligodendrocytes in vitro, and IL-10 induces 
proliferation and differentiation of neuronal stem cells in vivo. Neurons and microglia can induce 
Foxp3-expression and a regulatory phenotype in CD4+ T cells (green arrows) through secretion of 
TGF-β and B7/CD28 interaction or secretion of IL-10 in combination with low expression of co-
stimulatory molecules, respectively. In addition, several factors secreted by glial and neuronal cells 
promote CNS infiltration of peripheral Treg (not depicted, for details see main text). 
CNS-infiltrating Treg inhibit microglial pro-inflammatory responses [70]. As shown by 
proteome analyses, co-cultivation with Treg modulates microglial activity in vitro, including 
Figure 2. Examples of interactions between regulatory T cells (Treg) and cells of the central nervous
system (CNS). Treg influence the function and phenotype of resident CNS cells (black arrows, boxes).
For instance, Treg alter microglial responses and suppress astrogliosis via secretion of amphiregulin
(AREG) and cytokines, as well as through cell contact-dependent mechanisms. Moreover, Treg are
involved in CNS regeneration: Treg-derived cellular network communication factor 3 (CCN3) promotes
(re)myelination and differentiation of mature oligodendrocytes in vitro, and IL-10 induces proliferation
and differentiation of neuronal stem cells i vivo. Neurons and microglia can induce Foxp3-expression
and a regulatory phenotype in CD4+ T cells (green arrows) through secretion of TGF-β and B7/CD28
interaction or secretion of IL-10 in combina with ow expr ssion of co-stimulatory mo ecules,
respectively. In addition, several factors secreted by glial and neuronal cells promote CNS infiltration
of peripheral Treg (not depicted, for details see main text).
CNS-infiltrating Treg inhibit microglial pro-inflammatory responses [70]. As shown by proteome
analyses, co-cultivation with Treg modulates microglial activity in vitro, including inhibition of
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oxidative stress, cell migration, phagocytosis, and cytokine production. Treg are able to induce
apoptosis of activated microglia [71,72]. Moreover, Treg induce a neuroprotective M2-phenotype
of microglia with reduced production of neurotoxic factors, such as inducible nitric oxide synthase
(iNOS) and nitric oxide [70,73,74]. Brain Treg also suppress neurotoxic astrogliosis through secretion
of the low-affinity epidermal growth factor receptor ligand amphiregulin (AREG), as observed in
ischemic stroke mouse models. In contrast to other non-lymphoid tissues (e.g. intestine), the CNS
is an immune-privileged compartment and largely devoid of Treg in steady state. However, a
population of T cell receptor (TCR)αβ+CD4+Foxp3+ Treg has been found in the CNS of normal rats
under non-inflammatory conditions, located mainly in the cerebral cortex. These Treg cells show
an activated/memory phenotype characterized by the expression of inducible T cell costimulator
(ICOS, also referred to as CD278), CD103, KLRG1, and CTLA-4. They express high levels of IL-10
and have the ability to suppress conventional T cells and restrain pro-inflammatory responses of
microglia/macrophages in vitro [75].
Upon contact with resident CNS cells, naïve CD4+ T cells can convert to iTreg in vitro. Cytokine
secretion and activation state of CNS myeloid cells directly influence T cell polarity. As found in vitro,
IL-10 expression in microglia together with reduced expression of co-stimulatory molecules (CD40,
CD80) promoted de novo induction of Foxp3 and the proliferation of pre-existing Treg in co-cultured
CD4+ T cells [76]. These data indicate that mild CNS inflammation with low interferon (IFN)-γ levels
induce a tolerogenic phenotype of microglia that favors expansion of Treg in the CNS. Similarly,
co-incubation of astrocytes and lymphocytes induces T cells with suppressive properties, and supports
the polarization of CD4+ T cells into Treg in vitro [77,78]. Astrocytes sustain Foxp3 expression in
Treg through IL2/signal transducer and activator of transcription (STAT)5 signaling [75]. Moreover,
interaction between neurons and T cells results in conversion of autoreactive T cells to Treg, which
requires TGF-β [69]. Interestingly, adoptive transfer of Treg generated in glial and neuronal co-cultures
suppresses encephalitogenic T cells and reduces the severity of EAE in rodents [69,76,78]. Although
the extent to which peripheral T cells convert in the brain in autoimmune conditions is discussed
controversially [79,80], these data indicate that Treg expansion is influenced by the crosstalk between
lymphocytes and resident cells and the inflammatory environment in the CNS.
Besides their function in suppressing and terminating CNS inflammatory responses [81],
Treg have been shown to promote neural tissue repair along with proliferation and differentiation
of stem cells. Treg-secreted factors (Treg-conditioned media) enhanced the portion of myelin
basic protein-expressing oligodendrocytes in murine mixed neuron-glia cultures and organotypic
brain slices [82,83]. The Treg-derived growth regulatory protein CCN3 was shown to promote
oligodendrocyte differentiation and myelination in vitro [83,84]. In addition, Treg-activated M2-type
macrophages promote remyelination and differentiation of oligodendrocytes in the CNS [83,85].
Treg enhance neuronal stem cell proliferation in vitro and in the subventricular zone of ischemic mice
in vivo. The beneficial effect of Treg on neurogenesis following brain injury is mediated through IL-10
signaling [86].
In contrast to their therapeutic effects in primarily autoimmune disorders and their potential to
promote neural recovery, Treg reduce the protective antitumoral immunity and worsen the prognosis
in neoplastic diseases of the CNS [87]. Opposing and probably disease phase-dependent effects of
Treg have been described in animal models of neurodegenerative disorders and CNS injury [68,88,89].
Similarly, ambivalent functions of Treg can be observed in infectious disorders of the CNS (see below).
4. Regulatory T Cells in Virus Infection of the Nervous System
4.1. Role of Regulatory T Cells in Viral Encephalitis of Humans and their Animal Models
4.1.1. Regulatory T Cells Show Neuroprotective and Antiviral Effects in Retroviral Encephalitis
Human immunodeficiency virus (HIV) causes a progressive loss of immune function,
which increases the susceptibility to opportunistic infection and neoplasms. Infection of the brain is
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commonly associated with neuroinflammatory and neurodegenerative changes (Table 1), which leads
to neurocognitive dysfunction in up to 50% of patients [90]. HIV-1-associated neurocognitive disorders
(HAND) occur in advanced infections and encompass cognitive, motor, and behavioral abnormalities,
ranging from subtle deficits to severe dementia resulting from encephalitis. The pathogenesis of HAND
is not fully understood, but local virus replication and neuroinflammation are implicated in functional
and structural damage to neural tissue. Microglial cells are one of the main reservoirs of latent HIV-1,
and microglial activation is involved in the development of CNS lesions in HAND [91]. HIV-1-induced
neuronal damage can be modeled in mice by intracranial injection of bone marrow-derived macrophages
infected with a modified HIV-1 virus [92,93].
The role of Treg in the pathogenesis of systemic HIV infection remains controversial. Treg have
been suggested to suppress retrovirus-specific immunity and inhibit viral clearance. In contrast, others
describe a beneficial effect of Treg and their involvement in the inhibition of immune hyperactivation
and control of viral load [35,94]. In a murine model of HIV encephalitis, protective effects of Treg
on neuropathology and viral load were observed (Table 2). Herein, adoptively transferred green
fluorescent protein (GFP)-labeled CD4+CD25+ Treg migrated across the blood–brain barrier and
accumulated at sites of virus-induced inflammation in the murine brain [92]. The adoptive transfer of
Treg into HIV-infected mice prevented neuronal damage. This was associated with reduced CD4+ T cell
numbers, astrogliosis, microglial responses, tumor necrosis factor (TNF)-α expression and oxidative
stress in the CNS. Moreover, transferred Treg enhanced the secretion of brain-derived (BDNF) and
glial cell line-derived neurotrophic factor (GDNF) in infected rodents [93]. Using murine and human
primary cell cultures, Treg have been shown to reduce iNOS and elevate arginase-1 protein levels
in HIV-infected macrophages, indicating a switch from a neurotoxic M1 phenotype toward a M2
phenotype. These transformed myeloid cells were shown to exhibit neuroprotective properties in vitro,
such as preserving dendrite morphology of cultured neurons [55].
Strikingly, Treg are also able to reduce viral loads in the brain of HIV-infected mice by increasing
apoptosis of HIV-infected macrophages [93]. In vitro, Treg inhibited viral replication and release
and actively killed HIV-infected macrophages by caspase-3 and perforin/granzyme-dependent
pathways. The lethal effect on macrophages was markedly higher in infected compared to
non-infected cells. In addition, co-cultivation with Treg induced proteomic changes in HIV-1-infected
macrophages, characterized by upregulation of proteins related to antiviral immune responses,
apoptosis, cell shape/motility, and metabolism, indicating that Treg function by a broad range of
mechanisms to modulate the outcome of retroviral infection [55].
Collectively, these data indicate that although Treg may contribute to viral persistence in
the periphery, CNS-infiltrating Treg have the potential to locally control HIV infection, resolve
neuroinflammation, and promote neuronal survival in retroviral encephalitis.
4.1.2. Regulatory T Cells Inhibit Antiviral Immunity and Facilitate Virus Latency and Spread, but also
Protect from Excessive Immunopathology in Herpesvirus Infection
Infections with herpes simplex virus (HSV)-1 and -2 cause life-long virus latency and are the most
common causes of sporadic fatal encephalitis in humans. Necrotizing encephalitis and myelitis (Table 1)
can develop upon primary infection or reactivation of latent virus in ganglia [3]. Although HSV-1 is
responsible for the majority of HSV encephalitis cases in adults and children, neonatal infection is
often caused by HSV-2 [95]. Several studies have investigated the impact of Treg manipulation on
HSV-infection outcome in mice. The results are partially contradictory, as positive and negative effects
of Treg modulation are observed with respect to antiviral immunity (Table 2). Aside from the effects on
viral load, Treg have been shown to dampen immunopathology in the CNS and eye in mouse models
of HSV-infection.
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Table 2. Role of regulatory T cells (Treg) in animal models of neurotropic virus infections, determined by direct Treg manipulation.
Model Genetic Backgroundof Mice
Method of Regulatory T
Cell Manipulation Timeframe Effects on Antiviral Immunity Effects on Immunopathology References
Retroviridae
HIV-1 encephalitis
model C57BL/6
Adoptive Treg transfer;
Treg co-culture in vitro
Acute infection (Treg
transfer: 1 dpi, analysis:
7 dpi)
Beneficial:Treg reduce viral replication
and release, and destroy HIV-1-infected
macrophages via caspase-3 and
granzyme/perforin pathways
Beneficial: In vivo: Treg protect from
neuronal loss, increase neurotrophic
factor production, and reduce
neuroinflammation In vitro: Treg
induce proteomic changes in
HIV-infected macrophages and
transform them from M1 to M2
phenotype
[55,92,93]
Herpesviridae
Ocular HSV-1
infection BalB/c
DT-mediated Foxp3
ablation with or w/o
adoptive Treg transfer
Acute infection (depletion:
4–6 dpi, analysis: 28 dpi)
and latent infection
(depletion: 26–27 dpi,
analysis: 36 dpi)
Detrimental: Acute phase: Treg facilitate
establishment of latency in trigeminl
ganglia Latent phase: Treg are involved in
stress-induced reactivation of latent
infection
n.d. [96]
Subcutaneous
HSV-2 infection C57BL/6
Antibody
(CD25)-mediated Treg
depletion or DT-mediated
Foxp3 ablation
Acute infection(Treg
depletion: -3 dpi,
analysis: until 4 dpi)
Detrimental: Treg inhibit virus-specific
CD4+ and CD8+ T cell responses,
leading to increased viral load in the
CNS of neonatal mice
n.d. [97,98]
Intranasal HSV-1
infection BALB/c
Vitamin E-deficient diet;
antibody (CD25)
mediated Treg depletion
Acute infection(diet: 4
weeks prior to infection;
Treg depletion: -2 and 6
dpi, analysis: until 9 dpi)
Detrimental: Increased peripheral and
CNS Treg numbers in vitamin
E-deficient mice are associated with
reduced trafficking of virus-specific
CD8+T cells and increased viral load in
the CNS
n.d. [99]
Genital HSV-2
infection C57BL/6
DT-mediated Foxp3
ablation with or w/o Treg
transfer
Acute infection (Treg
depletion: -2, 0, 3 dpi,
analysis: úntil 12 dpi)
Beneficial: Treg limit initial replication
and virus spread into the CNS by
promoting entry of immune cells into
the infection site
n.d. [100]
Intracerebro-
ventricular
MCMV infection
C57BL/6 DT-mediated Foxp3ablation
Acute-chronic infection
(Treg depletion: -1, 1, 4
dpi, analysis: until 30 or
40 dpi)
Beneficial: Treg promote long-term
immunity by supporting transition of
effector T cells to tissue resident memory
T cells
Beneficial: Treg reduce T cell
numbers in acute encephalitis and
supress microgliosis, astrogliosis,
MHC class II expression,
hippocampal neurotoxicity, and
cognitive impairment in
post-encephalitic phase
[101,102]
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Table 2. Cont.
Model Genetic Backgroundof Mice
Method of Regulatory T
Cell Manipulation Timeframe Effects on Antiviral Immunity Effects on Immunopathology References
Flaviviridae
Subcutaneous
WNV infection C57BL/6
DT-mediated Foxp3
ablation
Acute infection (Treg
depletion: -1, 0 dpi,
analysis: until 20 or
60 dpi)
No effect on viral load in acute infection;
Treg limit effector T cell and
inflammatory cytokine responses in
acute encephalitis, but increase numbers
of potentially protective memory T cells
at later stages
Beneficial: Treg reduce morbidity
and mortality in acute WNV
encephalitis, presumably by
reducing immunopathology
[103,104]
Intraperitoneal
JEV infection C57BL/6
CCR5-/- mice with or w/o
CCR5+ Treg or CCR+
Treg transfer
Acute infection (Treg
tranfer: 3 dpi, analysis:
until 15 dpi)
No effect
CCR5-mediated CNS homing of
IL-10- and TGF-β-producing Treg
reduces neuro-inflammation
[105]
Paramyxoviridae
Intracerebral
infection with
recombinant MV
C57BL/6
Treg expansion by
superagonistic
CD28-antibodies;
DT-mediated Foxp3
ablation
Persistent infection (Treg
expansion: 14, 21 dpi,
Treg depletion: 17–20 dpi,
analysis: 28 dpi)
Detrimental: Treg inhibit virus-specific
CD8+ T cell responses leading to
increased virus replication in the
persistently infected CNS
n.d. [106]
Intracerebral
infection with
recombinant MV
C57BL/6, B6.129
Asm deficiency/blockade
with or w/o concurrent
DT-mediated Foxp3
ablation
Persistent infection (Asm
blockade with or w/o
Treg depletion: 21–26 dpi,
analysis: 28 dpi)
Detrimental: Deficiency or inhibition of
Asm leads to an elevated Treg to T
effector ratio and results in increased
virus replication (effect is
Treg-dependent); no effect on viral load
of Treg-depletion alone
n.d. [107]
Abbreviations: Asm: acid sphingomyelinase; CNS: central nervous system; dpi: days post infection; DT: diphtheria toxin; Foxp3: forkhead box protein P3; HIV: human immunodeficiency
virus; HSV: herpes simplex virus; IL: interleukin; JEV: Japanese encephalitis virus; MCMV: murine cytomegalovirus; MHC: major histocompatibility complex; MV: measles virus; n.d.: not
determined; IL: Interleukin; TGF: transforming growth factor; Treg: regulatory T cell; WNV: West Nile virus.
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Involvement of Regulatory T Cells in the Establishment and Reactivation of Latency
HSV infection triggers the expansion and activation Treg in lymphoid organs and at sites of
inflammation in humans and mice, which putatively suppresses antiviral responses and contributes
to immune evasion and the establishment of chronic infection or latency [96,97]. In the setting of
ocular HSV-1 infection of mice, an inhibitory effect of Treg on antiviral immunity was demonstrated in
experiments involving DT-mediated Foxp3 depletion. The model was characterized by an initial lytic
phase with high-level virus replication at the infection site and within trigeminal ganglia, which is
followed by virus clearance in the eye and establishment of latency in ganglia [96].
Treg co-localize with HSV-1 in the eye and trigeminal ganglia during acute and latent infection,
resulting in suppression of cytotoxicity and antiviral cytokine production. Experiments involving
DT-mediated Treg depletion and adoptive Treg transfer have demonstrated that this Treg influx
provides critical assistance for the establishment of latency. Moreover, stress-induced reactivation of
HSV-1 involves Treg expansion, which is presumably driven by glucocorticoid release [96]. Noteworthy,
in contrast to mouse models of HSV-1 latency, virtually no Foxp3+ cells have been found in infected
trigeminal ganglia in humans, despite the presence of CD8+ T cells, showing that human HSV-1
infection cannot be fully recapitulated by mouse models [108].
Involvement of Regulatory T Cells in Herpesvirus Spread to the Central Nervous System
Besides their role in latency and reactivation in ganglia, excessive Treg activity might also be
involved in virus spread into the CNS and initiation of encephalitis, as shown in ocular, subcutaneous,
and intranasal HSV infection.
In the ocular infection model, the Treg/T effector ratio was manipulated indirectly by influencing
glucose metabolism. Limiting glucose utilization by the drug 2-deoxy-glycose reduces effector Th1 and
innate immune cells but does not affect Treg frequencies in HSV-1-infected mice, leading to a skewed
Treg/T effector ratio. Administration of the drug starting in the acute phase (from 0 dpi onwards)
of ocular HSV-1 infection when replicating the virus is present in the eye, leads to reduced antiviral
immunity and viral spread to the brain, resulting in fatal encephalitis. This effect appears to be disease
phase-specific, as drug administration at later time-points (from 5 dpi), when viral load is low to absent
in the eye, does not lead to fatal disease and shows protective effects on ocular immunopathology [109].
In the subcutaneous HSV-2 infection model, Treg suppression via anti-CD25 antibodies prior to
infection enhanced early HSV-2-specific cytotoxicity and IFN-γ responses in neonatal and adult mice.
In neonatal mice, this resulted in lower HSV-2 titers in the lymph nodes and CNS during acute infection,
whereas no effects on viral load occurred in adults [98]. This supports the view that Treg responses of
the immature immune system inhibit antiviral immunity, and can explain the increased susceptibility
to lethal infections observed in human infants [98]. Moreover, Treg-depletion prior to infection using
anti-CD25 antibodies or genetic Foxp3-ablation enhances innate and adaptive immune responses
and increases IFN-γ production of CD8+ T cells in ganglia. Improved antiviral immune responses
in Treg-depleted mice reduce HSV-2 infection in ganglia and decrease the severity of recurrent skin
lesions from ganglionic spread [97].
Intranasal infection of mice with HSV-1 results in viral spread into the CNS along olfactory
and trigeminal nerves. In this model, vitamin E deficiency was shown to increase Treg numbers in
the periphery and the brain of infected mice, which was associated with decreased trafficking of
IFN-γ-expressing CD8+T cells to the brain. Antibody-mediated Treg depletion prior to and during early
infection (0-6 dpi) restores antigen-specific CD8+ T cell migration to the brain in vitamin E-deficient
mice. However, probably due to a delayed onset of protective T cell responses, Treg-depletion fails to
decrease the virus load and encephalic symptoms in this setting. Taken together, the timing of interplay
between Treg and effector T cells during acute infection seems to be important for T cell trafficking to
the brain, resolution of HSV-1 infection, and control of neurologic disease [99].
The described reports are in contrast with the findings described by Lund et al., which proposed
an involvement of Treg in protection from virus spread to the CNS using genital HSV-2 infection [100].
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In this model, the virus initially replicates in the vaginal mucosa and subsequently spreads into the
CNS via retrograde trasport to the sacral ganglia, which results in fatal paralysis. In genital HSV-2
infection of mice, Foxp3-ablation prior to and during early infection led to a rapid fatal infection with
an increased viral load in the spinal cord and neurologic deficits (hind limb paralysis), indicating
that Treg facilitate protective immunity in the context of genital HSV-1 infection. Treg-deprived mice
showed an increased chemokine ligand (CXCL)10, CCL2, CXCL9, and CXCL13 expression in innate
immune cells in lymph nodes, but profoundly reduced INF production and immune cell numbers
at the infection site. The pro-inflammatory chemokine secretion might cause an enhanced entry and
retention of lymphocytes in lymphoid tissues, leading to a delayed recruitment of effector T cells,
natural killer cells, and dendritic cells to the site of infection. The study indicates that Treg facilitate
early protective responses to acute HSV infection by allowing a timely entry of immune cells into
infected tissues [100].
The opposing effects of Treg manipulation on virus spread observed in the various murine models
might be attributed to differences in infection route (e.g., ocular, cutaneous, nasal vs. genital) or other
factors (e.g. genetic background and age of animals, Treg manipulation strategy, timing of modulation).
Involvement of Regulatory T Cells in the Suppression of Immunopathology
Besides their involvement in virus spread, studies in herpesvirus models have demonstrated a
substantial involvement of Treg in suppressing excessive immunopathology in the CNS. In murine
ocular HSV-1 infection, rapid antiviral treatment with aciclovir (≤ 2 dpi) protects from encephalitis by
reducing CNS infection. However, when treatment is delayed (≥ 4 dpi), encephalitis escalates despite
drug-induced virus control [110]. In a study conducted in mice receiving aciclovir at 4 days post
HSV-1 infection, neuroprotective effects of Treg were demonstrated. Oral administration of Bacteroides
fragilis polysaccharide A, an immunomodulatory bacterial component, induced CD39+CD73+ Treg
and protected mice from fatal encephalitis following HSV-1 infection and delayed antiviral treatment.
The bacterial symbiosis factor promoted IL-10 secretion by Treg and other cells, which restrained
myeloid cell infiltration in the brain stem and pathogenic innate immune responses. This observation
supports the idea that combinatorial treatment of an immunomodulatory compound and antiviral
drug may be an effective treatment strategy for viral inflammatory diseases [110].
A protective role of Treg on neuroinflammation was also demonstrated in murine cytomegalovirus
(MCMV) infection. MCMV encephalitis is a model for long-term neuroinflammation, characterized by
immune cell infiltration from the periphery, activation of microglia, and secretion of pro-inflammatory
cytokines, which persists even in the absence of detectable viral antigen. The inflammation is
accompanied by local Treg accumulation, which is enhanced by IL-10-secreting B cells [111]. In the
MCMV model, Treg prevented chronic neurologic dysfunction by controlling the development of
reactive astro- and microgliosis in infected mice. It has been shown that Foxp3-depletion during
acute MCMV infection enhances chronic glial cell responses, which heightens hippocampal damage
and cognitive impairment in the post-encephalic phase [101,111]. Furthermore, Treg support the
transition of effector T cells to tissue resident memory T cell in the CNS following MCMV infection.
This CD103+CD8+ memory T cell population in MCMV-infected mice shows an enhanced cytotoxic
activity (granzyme B release) upon antigen re-stimulation, which has the potential to control reinfection
and reactivation of latent or persistent infection [102].
In summary, the majority of studies in HSV-1 or -2 infections show that Treg can negatively
influence antiviral immunity, leading to systemic virus spread, CNS invasion, encephalitis, and
lethality. However, dependent on the infection route, positive effects on local immune responses
have also been demonstrated. This indicates that Treg might have different functions in distinct
tissue sites. In scenarios with reduced viral replication (e.g., with concurrent antiviral treatment or in
chronic MCMV infection), Treg seem to exert predominantly beneficial effects, as they ameliorate fatal
immunopathology and aid in the establishment of immunologic memory.
Int. J. Mol. Sci. 2020, 21, 1705 12 of 30
4.1.3. Regulatory T Cells Protect from Excessive Immunopathology in Acute Flaviviral Encephalitis,
but Might Be Involved in the Establishment of Neuroinvasion
Flaviviruses transmitted by mosquitos or ticks are important causes of epidemic
(meningo)encephalitis (Table 1), and are capable of causing serious morbidity and mortality [112].
West Nile virus (WNV) infection of humans is asymptomatic in approximately80% of cases and leads
to a self-limiting febrile illness (West Nile fever) in the remaining 20%. Less than 1% of individuals
develop a severe and potentially life-threatening neuroinvasive disease, which can result in long-term
neurologic impairment in survivors [3,113]. The host factors responsible for development of neurologic
disease are still largely elusive. On the one hand, an ineffective antiviral immune response can lead to
neuroinvasion and virus persistence in the CNS, causing direct and indirect inflammation-induced
damage. Long-term persistence of viral RNA has been reported following WNV infection and
WNV-specific immunglobin M( IgM) antibodies have been detected up to 5 months post-infection in
the cerebrospinal fluid (CSF) of patients with neurologic symptoms, indicating that virus persistence
might be at least in part responsible for disease [114,115]. On the other hand, there is evidence that
clinical disease is the result of immune-mediated damage caused by excessive immune responses,
rather than neuroinvasion alone [116,117].
Japanese encephalitis virus (JEV) infection can cause an acute encephalitis resulting in mortality
in up to 30% of cases, predominantly in infants. Approximately 50% of survivors develop serious
neuropsychiatric sequelae, which are considered more fatal than WNV infection, given the fatality rate
of 3%–5% [3]. Many aspects of the pathogenesis have been deciphered in rodent models of the disease.
Following infection, JEV replicates in dendritic cells and macrophages in the periphery. CNS invasion
is considered as the consequence of immune escape of the virus and crossing of the blood-brain barrier.
Although JEV is able to kill neurons directly, it is also believed that an impaired blood-brain barrier and
excessive secretion of pro-inflammatory cytokines, such as IL6 and TNF-a by infiltrating monocytes
and activated microglia, markedly contribute to neuropathology and disease development [118,119].
Beneficial effects of elevated Treg numbers on the disease outcome have been suggested in
humans and have been demonstrated in animal models of flavivirus encephalitis. However, animal
experiments also indicate that Treg have negative effects on antiviral immunity and facilitate virus
spread to the CNS.
Role of Regulatory T Cells in West Nile Virus Infection
In a cohort of 32 human patients with acute WNV infection, increased blood Treg levels
were strongly correlated with asymptomatic infection [103]. In a different study, investigating
12 asymptomatic subjects and 12 patients with neuroinvasive disease, no differences were observed
regarding overall Treg frequencies, but Treg from human patients with neurologic disease showed
reduced CTLA-4 expression, suggestive of a reduced suppressive capacity. Moreover, these patients
showed generally elevated, dysregulated, and atypically polarized T cell responses, which could
be secondary to a diminished Treg function [116]. Therefore, a robust early Treg expansion might
protect from symptomatic disease through dampening WNV-specific immune responses and associated
immune-mediated damage [103,117]. The limitations of these studies are that samples were collected
after infection of an unknown duration, and assessment of the pre-infection Treg levels was not possible.
Moreover, the analysis of peripheral blood samples might not ideally reflect the situation in the CNS.
Studies deciphering the connection of baseline Treg levels and infection outcome have been performed
in animal models of WNV infection.
Similar to humans, lower Treg levels can be found in C57BL/6 mice that succumb to acute WNV
infection and increased frequencies of Treg expressing the activation and migration markers CD44, ICOS,
and chemokine receptor (CXCR) 3 are associated with protection from clinically apparent neurologic
disease [103,120]. Moreover, mice depleted of Treg prior to infection show increased neurologic disease
symptoms and mortality following WNV infection [103]. Strikingly, although Treg-ablated mice
exhibited higher frequencies of IFN-γ-producing, virus-specific T cells in the CNS during acute WNV
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infection, memory CD8+ T cell responses were impaired in later phases. Treg-mediated production of
TGF-β resulted in an increase in CD103+CD8+ resident memory T cells in the brain at 60 dpi, indicating
that Treg are able to maintain the brain resident memory population and potentiate antiviral immunity
in WNV infection. Importantly, the effects on memory T cells were observed despite the fact that Treg
depletion was only transient and performed prior to infection. The authors hypothesized that following
infection, Treg might function to suppress a vigorous antiviral immune response to limit tissue damage
at the cost of rapid virus clearance, but simultaneously protect the host from uncontrolled replication of
persisting virus by aiding the development of a tissue resident memory T cell population [104]. This was
supported by an experiment performed in mice on a broader genetic background. In order to identify
factors that predispose to neuroinvasion and/or clinical disease, WNV infection was investigated
using the collaborative cross (CC), composed of many different recombinant mouse lines with high
levels of genetic variation, which models genetic diversity found in human populations. Similar to
humans, individual CC strains show variable outcomes following WNV infection in terms of survival,
clinical disease score, viral titer, and innate and adaptive immune responses in peripheral tissues and
the CNS [121,122]. A correlation analysis of the infection outcome and immunophenotype suggests
beneficial and detrimental effects of Treg, depending on the investigated parameter and time-point.
Regarding the distribution and persistence of virus in CNS tissues, Treg seems to play a detrimental
role. Reduced expression of activation markers on splenic Treg before infection are associated with
peripheral virus restriction, suggesting that reduced suppressive activity of Treg under steady state
conditions assists in preventing WNV neuroinvasion [120]. Moreover, an early expansion of splenic
Treg with increased expression of CD73, CTLA-4, ICOS, glucocorticoid-induced tumor necrosis factor
receptor TNFR-related protein (GITR), and CD44, as well as CNS migration markers such as CXCR3
and CD29, correlates with the manifestation of chronic WNV infection. An early brain infiltration
of CD73+ Treg is associated with reduced cytolysis by natural killer cells and/or CD8+ T cells, likely
allowing for viral persistence [122]. Additionally, elevated Treg levels are present in the murine brain
during persistent WNV infection [123].
Taken together, prominent activation of the suppressive capacity and migratory ability of Treg
during the early WNV infection and even prior to infection is associated with the establishment of
chronic CNS infection. However, the connection between Treg and WNV persistence is based solely
on correlation analyses thus far, and further experiments are needed to determine cause and effect.
Treg depletion has been performed only in two experiments, and in one of them, viral load was not
assessed [103], whereas the other showed no difference in viral RNA between Treg-depleted and
non-depleted animals [104].
Importantly, not all CC mouse strains with neuroinfection develop clinical disease. In early
neuroinvasive infection, high numbers of Treg expressing the activation markers CD44 and ICOS and
the CNS migration marker CXCR3 correlate with protection from clinically apparent disease [120],
which is in agreement with the findings described above [103]. Therefore, based on the current
evidence, the beneficial effects of Treg seem to outweigh the possible impairment of antiviral immunity
in clinical terms during established encephalitis. Analogous to the findings in WNV infection, a relative
expansion of Treg compared to effector T cells is associated with reduced immunopathology and
protection from severe disease in acute dengue virus infection in children [124].
Role of Regulatory T Cells in Japanese Encephalitis Virus Infection
In a mouse model of JEV infection, protective effects of CCR5+Treg were demonstrated. CCR5
ablation in JEV-infected mice exacerbated encephalitis symptoms and mortality, which was associated
with reduced Treg responses and increased Th17 cell numbers in the brain. Adoptive transfer of
CCR5+Treg into CCR5−/− mice during development of encephalitis (3 dpi) reversed the phenomenon
by increasing IL-10 and TGF-β expression in the brain. These data showed a beneficial role of Treg in
dampening severe neuroinflammation following JEV infection, which depends on CCR5-mediated
homing to the CNS. It is worth mentioning that CCR5−/− animals with or without Treg-transfer have
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similar levels of virus in the CNS compared to JEV-infected wild-type animals, showing that neither
CCR5 nor Treg have an impact on virus control and that the effects of the manipulations are unrelated
to altered viral replication [105]. Interestingly, loss-of-function mutations in CCR5 are associated
with increased disease severity, but not increased susceptibility in WNV-infected humans [125,126].
Whether this association is also related to CNS homing of Treg remains to be determined. Aside
from CNS influx of peripherally generated or activated Treg, local generation of induced Treg might
also be involved in ameliorating flaviviral encephalitis. Co-culture experiments reveal that neural
stem/progenitor cells have the ability to convert encephalitogenic T cells isolated from JEV-infected
mice into Treg [127].
In contrast to the neuroprotective effects observed during encephalitis, an involvement of excessive
Treg activation in the periphery immediately following infection is suspected to contribute to immune
escape of the virus. JEV is thought to manipulate the host’s immune system to evade the immune
surveillance in the periphery and cross the blood–brain barrier. JEV infection led to disturbed
maturation of human and mouse dendritic cells in vitro and ex vivo, which was also associated
with elevated IL-10 production, programmed death-ligang 1 (PD-L1) expression, and expansion of
the Treg population [128–130]. In contrast, in vitro dendritic cell infection with attenuated JEV (live
vaccine) impaired the expansion of Treg, which might contribute to expansion of effector T cells and
development of protective antiviral immunity following vaccination with the strain [131]. Therefore,
similar to the situation in WNV infection, an initial induction of Treg putatively facilitates virus spread
and neuroinvasion immediately following infection. Thus far, this has only been shown using in vitro
or ex vivo culture of DCs. Further experiments are needed to determine the functional significance of
JEV-induced Treg expansion in vivo. An association of Treg numbers and antiviral immunity has also
been made in an animal experiment applying JEV-infected toll-like receptor (TLR)4-deficient mice.
TLR4−/− mice showed reduced viral CNS burden, lethality, and neuroinflammation, which is associated
with enhanced type I IFN innate immunity and virus-specific CD4+ and CD8+ T cell responses and
reduced Treg numbers. However, it remains unclear whether reduced Treg numbers in this setting
are the cause or the effect of decreased CNS infection and inflammation, and further experiments are
needed to demonstrate causality [132].
Role of Regulatory T Cells in Zika virus Infection
Zika virus infection during pregnancy causes developmental defects of the fetal CNS (Table 1).
Similar to JEV, Zika virus infection induces indoleamine 2,3-dioxygenase 1 (IDO-1) expression in
dendritic cells of human patients, which is thought to antagonize host antiviral immunity through Treg
induction [4]. However, whether the early increase in peripheral Treg observed in Zika virus-infected
mice affects protective immunity and contributes to neuroinvasive disease remains elusive [133].
In summary, there is direct evidence that Treg are capable of ameliorating immunopathology
occurring in flaviviral encephalitis with favorable consequences for the host’s neurologic function and
survival, once encephalitis is present. In vitro experiments and correlation analyses also suggest an
involvement of Treg in facilitating immune escape and neuroinvasion of flaviviruses. Nonetheless,
further experiments are needed to prove causality and functional relevance in vivo. From the
perspective of the virus, enhancement of immunomodulatory mechanisms that facilitate virus spread
but simultaneously ensures the survival of the host is certainly an advantage.
4.1.4. Regulatory T Cells Inhibit Antiviral Immunity in Persistent Measles Virus Infection of the
Central Nervous System
Mealses virus (MV) is a contagious respiratory pathogen that causes systemic disease and remains
an important cause of child mortality [134]. Measles inclusion body encephalitis is a neurologic
complication observed in immunocompromised individuals, which typically occurs within 1 year
following acute MV infection. Subacute sclerotizing panencephalitis (SSPE) occurs on average
4–10 years following acute infection. Both CNS manifestations are characterized by extensive infection
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of neurons and oligodendrocytes with perivascular inflammation, degenerative changes, and gliosis
(Table 1).
Elevated frequencies of circulating Treg can be observed in patients with acute measles, which
might contribute to transient immunosuppression [135,136]. In addition, as observed in measles virus
(MV)-infected rhesus macaques, Foxp3-expression in blood leukocytes correlated with slow viral
clearance and prolonged infection [137]. Treg have been shown to influence the level of MV in the
brain of persistently infected mice. In CD150-transgenic mice (which are susceptible to MV infection
through the introduction of the human MV-receptor), expansion of splenic Treg and migration of these
cells to the areas of viral replication in the brain can be observed following MV infection [138]. Treg
survival and function are partly dependent on CD28 signaling. Employing a mouse model of persistent
brain infection with recombinant MV, Treg expansion by superagonistic anti-CD28 antibodies (clone
D665) during chronic MV infection induced transient immunosuppression and subsequent increase in
virus replication and transneuronal spread in the mouse brain. Conversely, Foxp3-ablation in DEREG
mice in a similar disease phase enhanced virus-specific CD8+ effector T cell responses in the brain
and caused reduction in MV persistence [106,139]. Acid sphingomyelinase (Asm) deficiency increases
the frequency and suppressive activity of Treg. MV infection of Asm-deficient mice led to reduced
virus-specific CD8+ T cell responses and relatively enhanced Treg responses, resulting in massive brain
infection. Similarly, Asm inhibition by amitriptyline, an antidepressant drug, increases the number of
infected neurons in the mouse model persistent brain infection. The increase in viral brain load requires
the presence of Treg because Asm inhibitor treatment shows no effect on MV infection in Treg-deprived
mice [107]. Interestingly, in this study, Treg-depletion without Asm inhibition did not reproduce the
effects on viral replication described in the study by Reuter et al. [106]. This could be due to differences
in the protocol of Treg depletion (dose, time-point of DT administration) or due to different genetic
backgrounds of used mice (C57BL/6 vs. C57BL/6.129). Because the described model of persistent
MV infection did not produce clinically apparent disease and the neuropathologic sequelae were not
investigated, the significance of differences in viral replication for neurologic function are unknown.
Nevertheless, the reports indicated that manipulation of Treg in the periphery has consequences for the
fate of MV infection in the brain. A disproportional increase in Treg compared to conventional T cells
causes a poor control in MV infection, which may play a role in establishing persistent MV infection in
subacute sclerotizing panencephalitis (SSPE). However, because decreased frequencies of circulating
CD152+ Treg have been observed in SSPE patients, the role of peripheral and CNS infiltrating Treg in
maintaining persistent MV infection in humans remains unclear [140].
In summary, excessive Treg functions increase viral CNS load in a mouse model of persistent
MV infection.
4.1.5. Other Viruses
An increased type I immune response with unchanged Foxp3+ cell levels was found in blood
samples of influenza virus-infected children. In infected children with respiratory and neurologic
complications (acute necrotizing encephalopathy), a high percentage of perforin- and IFN-γ-expressing
CD4+ and CD8+ T cells, associated with low percentages of Treg were found, suggestive of a
dysregulated antiviral type I immune response in complicated influenza virus infection [141]. Exuberant
Th1 immune responses causing lethal meningoencephalitis in neonatal mice infected with Tacaribe
arenavirus are associated with minimal IL-10 increase and absence of Treg [142].
4.2. Regulatory T Cells in Animal Models for Virus-Induced Demyelinating Disorders
Myelin damage in the CNS occurs following different neurotropic virus infections, such as
JC virus (progressive multifocal leukoencephalopathy), MV (subacute sclerosing panencephalitis),
and HIV infection. Although no clear causal relationship between MS and viral infection has been
firmly established yet, viruses have been implicated in initiating or exacerbating MS symptoms.
Important mouse models to study the pathogenesis of virus-induced demyelination are Theiler’s
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murine encephalomyelitis virus (TMEV) and neurotropic mouse hepatitis virus (MHV) infection.
Infection with these viruses induces an acute encephalitis phase with virus replication within the CNS,
followed by a phase characterized by demyelination, which occurs despite control of viral replication,
and is driven by immunopathology or autoimmunity against myelin components. Because Treg-based
therapies have been considered as an attractive therapeutic option for demyelinating diseases of
humans, the effects of Treg manipulation in the context of virally-induced demyelination has been
studied in both models (Tables 3 and 4) [143,144].
4.2.1. Theiler’s murine encephalomyelitis virus model
Infection of SJL mice with Theiler’s murine encephalomyelitis virus (TMEV) causes a biphasic
disease with an acute and usually subclinical hippocampal infection, followed by a persistent infection
of the spinal cord with myelin-specific autoimmunity and a clinically apparent demyelinating disease
(TMEV-IDD), resembling chronic-progressive MS. By contrast, C57BL/6 mice eliminate the virus from
the CNS during early infection by means of a robust antiviral CD8+ T cell response and develop no
chronic disease [143].
A rapid systemic expansion and accelerated CNS infiltration of Treg were observed in SJL mice
but not in C57BL/6 mice during early TMEV infection [145,146]. An unfavorable ratio of Treg to effector
T cells during acute infection was proposed to inhibit antiviral cytotoxicity of TME-IDD-susceptible
mouse strains, which contributes to TMEV persistence in the spinal cord. This hypothesis was
tested in SJL mice by Treg-inactivation prior to TMEV infection using anti-CD25 and anti-GITR
antibodies (Table 3). Both methods resulted in enhanced antiviral CD4+ and CD8+ T cell responses
and TMEV-specific antibody production, which led to a reduced viral load in the CNS and delayed
onset of neurologic disease [146]. Conversely, application of ex vivo-induced Treg (iTreg) prior to
TMEV infection decreased CNS recruitment of leukocytes, resulting in increased virus replication
and occurrence of clinical symptoms in the acute infection phase, which is usually asymptomatic. By
contrast, Treg transfer during the chronic phase (3–4 weeks post infection) ameliorated demyelinating
disease without affecting viral titers. These data showed that Treg have disease phase-dependent
functions in the TME model, with detrimental effects on protective antiviral immunity during the
initial phase and protective effects during chronic persistent infection, which are presumably mediated
by suppression of virus-induced immunopathology [147]. Accordingly, beneficial effects of certain
experimental treatments and pharmaceutical agents have been linked to increased Treg functions in the
TMEV model. Dysbiosis induced by oral antibiotic administration prevented motor dysfunction and
spinal axonopathy in TMEV-infected SJL mice, and the neuroprotective effect involved an enhanced CNS
infiltration of CD39+ Treg [148]. Similarly, application of glatiramer acetate, an immunomodulatory
drug used in MS treatment, improved clinical disease in TMEV-infected SJL mice with enhanced
endogenous Treg responses and IL-10 production, but without affecting antiviral immunity [149].
In contrast to SJL mice, antibody-mediated Treg-depletion exhibited no impact on antiviral
immunity in TMEV-IDD-resistant C57BL/6 mice [146]. Similarly, Foxp3-ablation in DEREG mice
(C57BL/6 background) did not reduce the cerebral virus load, despite enhancing CNS recruitment of
IFN-γ producing T cells [150]. Moreover, adaptive transfer of iTreg or expansion of endogenous Treg
with IL-2 immune complexes failed to diminish virus clearance or to induce demyelination in C57BL/6
mice [147,151]. However, Treg expansion in combination with antibody-mediated CD8-depletion
in C57BL/6 mice led to chronic TMEV infection with myelin loss and axonal damage in the spinal
cord [151]. The combination of both manipulations resulted in a delayed recovery of depleted CD8+ T
cells, which interfered with virus clearance. This finding indicates that, rather than the magnitude of
Treg responses alone, the balance of Treg and CD8+ effector T cells instead is crucial to control virus
replication upon acute infection. The lack of Treg-mediated effects on antiviral responses indicates that
the function of Treg is overridden by the vigorous antiviral CD8+ T cell response in TME-IDD resistant
C57BL/6 mice.
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
or
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delay d chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Gla iramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
inv stigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of anipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** o effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Incr ase or ⇩ decr a e f regulat ry T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the diseas  phase (pre-infecti n: before or at the day of intracranial infection; 
a ute infectio : 1–2 weeks post infection; chronic infection: 3–4 we ks p st fection). ** Indirect effect 
on Treg. Abbr viations: DEREG: deplet on of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summar , detrimental effects of Treg on a tiviral immunity depend on the gen tic 
background of the animal, ti ing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain One of the most potent effectors secre ed by Treg is IL-10, and elevated l vels of 
the cytokine have been detected in i s of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV infected SJL mice treated with ant bodies blocking th  IL-10 receptor, 
no p sitive effect on viral load i  the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually on  inimal or absent in SJL mi e [152]. Thu , IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral imm nity is m st likel  mediated by other Treg effector functions. 
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T b e 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
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Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pr -infection 
Antibody–mediated 
deple on 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
hronic 
infec
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infec
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infec
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase r ⇩ decrease of regulat ry T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to he dise se phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post inf ion; hronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbr viations: DEREG: d pletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocor icoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune compl xes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In sum ary, detrime tal effects of Treg on antiviral immunity depend on the genetic 
background of the anim l, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechan sms, by which Tr g ex t their suppressive function in early TMEV-infection of SJL mice, 
r main uncertain. One of the most potent ffectors secreted by Treg is IL-10, and elevated levels of 
the cy okine have been det cted in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load n th b ai  r the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which s ually only minimal o  absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
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Table 3. Effects of regulatory T cell anipulation on viral load and disease in Theiler’s urine 
encephalo yelitis virus infection. 
Virus 
Strain 
ouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
anipulation
* 
ethod Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-i fecti  
Adoptive transfer of x 
vivo g nerated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No ffect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiram r a etate** No eff ct 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
i f cti  
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
d pletion 
(anti CD25) 
No eff ct No eff ct [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-m di ted depl tion 
in DEREG mice 
No ffect No ffect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [ 51] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrea e of regulatory T cell (Treg) nu bers, viral load, r diseas . * Ti e of  
anipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 eeks post infection; chronic infection: 3–4 eeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell ice (C57BL/6 background); GITR: 
glucocorticoid-induced tu or necrosis factor-receptor (T FR)-related protein; IL2C: interleukin (IL) 
2 i une co plexes consisting of reco binant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In su ary, detri ental effects of Treg on antiviral i unity depend on the genetic 
background of the ani al, ti ing of anipulation, and the integrity of cytotoxic responses (Table 3). 
The echanis s, by hich Treg exert their suppressive function in early T EV-infection of SJL ice, 
re ain uncertain. ne of the ost potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL ice co pared to lo er levels in 
C57BL/6 ice [145]. In T EV-infected SJL ice treated ith antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord as observed during acute or chronic 
infection [152,153]. o ever, IL-10 block de resulted in increased hippoca pal da age during acute 
infection, hich is usually only ini al or absent in SJL ice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective echanis  in acute T EV-infection, hereas the suppressive effect on 
antiviral i unity is ost likely ediated by other Treg effector functions. 
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T b e 3. Effects of regulatory T cell anipulation on viral load and disease in Theiler’s urine 
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⇩ or ⇧ 
Time of Treg 
anipulation
* 
ethod Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pr -infecti  
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
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infec
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infec
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infec
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ I crease r ⇩ decrease of regulat ry T cell (Treg) nu bers, viral load, or disease. * Ti e of Treg 
anipulation refers to he dise se phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 eeks post inf ion; hronic infection: 3–4 eeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell ice (C57BL/6 background); GITR: 
glucocor icoid-induced tu or necrosis factor-receptor (T FR)-related protein; IL2C: interleukin (IL) 
2 i une co pl xes consisting of reco binant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In su ary, detri e tal effects of Treg on antiviral i unity depend on the genetic 
background of the ani al, ti ing of anipulation, and the integrity of cytotoxic responses (Table 3). 
The echan s s, by hich Tr g exert their suppressive function in early T EV-infection of SJL ice, 
r ain uncertain. ne of the ost potent ffectors secreted by Treg is IL-10, and elevated levels of 
the cy okine have been det cted in brains of acutely infected SJL ice co pared to lo er levels in 
C57BL/6 ice [145]. In T EV-infected SJL ice treated ith antibodies blocking the IL-10 receptor, 
no positive effect on viral load in th b ain r the spinal cord as observed during acute or chronic 
infection [152,153]. o ever, IL-10 blockade resulted in increased hippoca pal da age during acute 
infection, hich is sually only ini al o  absent in SJL ice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective echanis  in acute T EV-infection, hereas the suppressive effect on 
antiviral i unity is ost likely ediated by other Treg effector functions. 
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-i f ction
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-ch onic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antib otics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated d pletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-i f ction
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
e cephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or  
Time of Treg 
Man pulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-i fecti  
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delay  chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pr -infection 
Adoptive t nsfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chro ic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chr nic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute- hronic 
infection 
Glatiramer acetate** No eff ct 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
i fecti  
Oral antibiotics** 
Not 
investigated 
Chroni  
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
o ffect o ffect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediate  depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo g nerated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-i tion 
Expansion by IL-2C, 
a t body-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrea e of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulati n refers to the disease phase (pre-inf cti n: before or t the day of intracranial infection; 
acute infecti n: 1–2 weeks post infection; chro ic infection: 3–4 weeks post infection). ** I direct effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protei ; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-anti odies; iTreg: induced Treg. 
I summary, d trimental effects of Treg on an viral immunity depend n th  genetic
backgr und of the animal, timing of ma ipulation, and the integrity of cytotox c respo ses (Table 3).
The mechanisms, by hich Treg exert their suppressive functio  in early TMEV-infection of SJL ice
r mai  unc rtain. One of the os  potent effector  secreted by Tr g i  I - , and elevated levels of
th  ytokine have be n d tected i  bra s of ac t ly infe t d SJL mic co pared to lowe  l vels in
C57BL/6 ice [145]. In TMEV-inf cted SJL mic  treated with antibod es blocking th  IL-10 receptor,
no positive effect on viral load in the bra or the spinal cord was obs rved during acute or chronic
infection [152,153]. However, IL-10 blocka e result d i  ncreased hippoca pal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuropr tective mechanism i  acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Chro ic
infection
Adoptive transfer of
ex vivo generated
iTreg
No effect
Chronic
de yelination
 
Table 3. Effects f regulat ry T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus i fection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generat  iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeA  C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effe t [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
B An C57BL/6 ⇧ Pre-inf  Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧
nd 
CD8⇩ 
Pre-infection 
Expa sio  by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decreas of re ulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation r rs to the disease phase (pre-infection: bef re or at the day of intracranial infection; 
acute infecti n: 1–2 w ek  post infection; chronic i fection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviatio s: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-indu ed tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immu e compl xes cons sting of r combinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brai  or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[147]
DA SJL/J
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
e cephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulati
* 
Method Viral Load Disea  
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatir mer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chro ic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediate  
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Tr ) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the diseas  phase (pre-infection: before or t the day of intracra ial infection; 
acute inf ction: 1–2 weeks p st infection; chronic inf ction: 3–4 weeks post infection). ** I direct effect 
on Treg. Abbreviations: DEREG: dep etion of g atory T cell mice (C57BL/6 background); GITR: 
gluc cortico d-ind ced tumor necros s f ct -receptor (TNFR)-related protein; IL2C: interl uki (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodi s; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral l ad in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective m chanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
** Acute-chronicinfecti Glatiramer acetate** No effect
Chronic
demyelination
 
Table 3. Effect  of regulat ry T cell mani ulation on viral load and disease in Theiler’s murine 
e cephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Tim  of Tr g 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyeli ation 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
inf ctio  
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeA  C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
o effect o effe t [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre- nfection 
Adoptive transfer of ex 
viv  generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-inf cti n Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Exp sion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ d cr as  o  regulatory T cell (Treg) numbers, viral load, or is ase. * Time of Treg 
manipulati n r f rs to the disease phas  (pre-inf cti n: before o  t the day of intracra ial infection; 
acute i fecti n: 1–2 weeks post infection; chro ic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucoco ticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immun  omplexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In sum ary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulati n, a d the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice co pared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuropr tective mechanism i  acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[149]
DA SJL/J
 
Table 3. Effects of regulatory T ell manipulation on viral load and disease in Theile ’s murine 
e cephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulati
* 
Method Viral Load D sea  
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR)
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatir mer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
o effect o effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No eff ct No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generat d iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infectio  
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chr nic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of egulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulati n refers t  the disease hase (pre-inf cti n: b fore or t the day of intr cranial inf ction; 
acute i fecti n: 1–2 weeks post infection; chro i  infec ion: 3–4 weeks post inf ction). ** Indirect effect 
on Treg. Abbreviations: DEREG: d pletion of regul ory T cell mice (C 7BL/6 background); GITR: 
glucocorticoid-induced tumor ecrosis factor-receptor (TNFR)-related pr tein; IL2C: interleukin (IL) 
2 mmune complexes consisting of recombinant IL-2 a d anti-IL-2-ant bodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Tabl  3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL m c , 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice co pared to lower l vels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuropr tective mechanism i  acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
** Chronicinfection Oral antibiotics**
Not
inv stigated
Chronic
demyelina ion
 
Table 3. Effect  of regulat ry T cell manipulati n on viral load and disease in Theiler’s murine 
e cephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Meth d Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infec
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Dela d chr ic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No ef ect 
Chronic 
demyelination ⇩ 
[147] 
D  SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** o effect 
Chronic 
demyelination ⇩ 
[149] 
D  SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
de yelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-inf ction 
Antibody-mediated 
dep etion 
(anti CD25) 
o effect o effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Ad ptive transfer of ex 
vivo generated iTreg 
No effe t No effect [147] 
BeAn C57BL/6 ⇧ Pre-inf ction Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansio  by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Incr ase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulati n refers to th isease phase (pre-inf cti : before or t the day of intracranial infection; 
acute infecti n: 1–2 eks post infection; chro ic infection: 3–4 w eks ost infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T ll mice (C57BL/6 backg ound); GITR: 
glucoco ticoid-induced tumor necro is factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immun  omplexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice co pared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuropr tective mechanism i  acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[148]
BeAn C57BL/6
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Tim  of Treg 
Ma ipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo ge e ted iTreg 
⇧ Acute disease  [147] 
DA SJL/J ⇧ 
Chronic 
i fecti  
Adoptive transfer of ex 
viv  generated iTreg
No effect 
Chronic 
demy li ation ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chr ic 
infection 
Glatiramer acetate** No effect 
Chronic 
demy li ation  
[149] 
DA SJL/J ⇧**
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-m diated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effec  [150] 
DA C57BL/6 ⇧ Pre-inf ction 
Adoptive transfer of ex 
vivo g n rated i reg 
No effect No effect [147] 
B An C57BL/6 ⇧ Pr -infection Expansion by IL-2C No ffect N  effect [151] 
B An C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pr -inf ction 
Expansion by IL-2C, 
antibody mediated 
CD8-depletion 
⇧ 
Chr nic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease  regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
ma ipulation refers to the disease ph se (pre-infectio : befor  or at t e day of intracranial i fecti n; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviation : DEREG: depletion of regul tory T c ll mice (C57BL/6 background); GITR:
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental eff cts of Treg on ant vir l immunity depend on the genetic 
background of the animal, ti i g of manipulation, a d the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mic , 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and levated levels of 
the cyt ki e have been detect d in brains of acutely infected SJL mice compared to low r levels in 
C57BL/6 ice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infecti n [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Pre-infection Antibody-mediateddepletio (anti CD25) No effect effect [146]
BeAn C57BL/6
 
Table 3. Effects of regulatory T cell manipul tion on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
train 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
M thod Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–med ated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
D  SJL/J  i ti  
Adoptive transfer of ex 
viv  generated iTreg 
⇧ Acute dis ase  47  
D  SJL/J ⇧ 
Chron c 
infectio  
Adoptive transfer of ex 
vivo ge erated iTreg 
o effect 
i  
li ti   
47  
D  SJL/J ⇧** 
Acute-chr ic 
infection 
Glatiramer acetat ** No effect 
Chronic 
de yelination ⇩ 
[149] 
DA SJL/J ** 
Chronic 
inf ti n 
Oral antibiotics** 
N t 
investigat d 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depleti  
(anti CD25) 
No effect No effect [146] 
Be n C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
o effect o effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transf r of ex 
vivo g ne ated iTreg 
No effect No effect [147] 
B n C57BL/6 ⇧ Pr -inf tion Exp nsion by IL-2C N  effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expa si n by IL-2C, 
antib dy-me iated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Incr ase or ⇩ decrease of regulatory T cell (Tr g) numbers, viral load, or disease. * Time f Treg 
manipulation refers to the disease p ase (pre-infection: before or at the day f intracra ial infection; 
ac te infection: 1–2 weeks post infectio ; chronic infection: 3–4 eeks po t infectio ). ** Indirect effect 
on Treg. Abbreviations: DEREG: depleti n of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-in uced tumor necrosis factor-receptor (TNFR)-relate  protein; IL2C: interleukin (IL) 
2 immune omplexes consist recombin nt IL-2 and ant -IL-2-antibodi s; iTreg: induced T eg. 
In su mary, detrimental effects of Treg on antiviral immunit  dep nd on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses ( able 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-inf cti  of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated l ls of 
the cytokine have been detected in brains of acutely infected SJL mice ompared to lower evels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocki g the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was obser ed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Pr -infection
DT-mediated
depletion in DEREG
mice
No effect No effect [150]
DA C57 L/6
 
Table 3. Effects of regulatory T c ll anipulation on viral load and disease in T eiler’s urine 
encephalo yelitis virus infection. 
Virus 
Strai  
ouse 
train 
Treg 
⇩ or ⇧ 
Time of Treg 
anipulation
* 
ethod Viral Load Disease 
Refer
ence 
Be n  ⇩  
Antibody–mediated 
depletion 
(anti-C 25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
6  
D  SJL/J  i ti  
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute dis ase ⇧ 147  
D  SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
i  
li ti   
47  
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiram r acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
D  SJL/J ** 
Chronic 
infecti n 
Oral antib tics** 
N t 
v gated 
Chronic 
demyeli at on ⇩ 
8  
 /   i ti  
Antibody-mediated 
depletion 
(anti CD25) 
 t   46  
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mi  
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptiv  transfer of ex 
vivo gene ated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No eff ct [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expa sion by IL-2C, 
antibody-me iated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ I crease or ⇩ decreas  of regulat ry T c ll (Treg) nu be s, viral load, r disease. * Ti e of Treg 
a ipulation refers to the disease phase (pre-infection: before or at the day f intracranial i fection; 
acute i ection: 1–2 eeks post inf ction; chronic infection: 3–4 eeks po t infection). ** Indir ct effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell ice (C57BL/6 backgroun ); GITR: 
glucocortico d-induced tu or necrosis factor-receptor (T FR)-related protein; IL2C: interleukin (IL) 
2 i u  co plex s consisting of reco binant IL-2 and anti-IL-2-antibodie ; iTreg: induced Tr g. 
In sum ary, detri ental effects of Treg on antiviral i unity depend on the g netic 
background of the ani al, ti ing of anipulation, and the integrity of cyt toxic responses ( able 3). 
The echanis s, by hich Treg exert their suppressive function in early T EV-inf cti n of SJL ice, 
re ain uncertain. ne of the ost potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL ice co pared to lo er levels in 
C57BL/6 ice [145]. In T EV-infected SJL ice treated ith antibodies blocki g the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord as observed during acute or chronic 
infection [152,153]. o ever, IL-10 blockade resulted in increased hippoca pal da age during acute 
infection, hich is usually only ini al or absent in SJL ice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective echanis  in acute T EV-infection, hereas the suppressive effect on 
antiviral i unity is ost likely ediated by other Treg effector functions. 
4.2.2. Coronavirus odel of e yelination 
Pre-inf ction
Adoptive transfer of
ex vivo ge erated
iTreg
ff t No effect [147]
BeAn C57 L/6
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease  Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Meth d Viral Load Disease 
Ref r
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
d pletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
 J /J  Pre-infection 
i     
i  t  i  
⇧ Acute disease ⇧ [ ] 
 J /J ⇧ 
r  
i f ti  
Adoptive transfer of ex 
vivo generated iTreg 
 ff t 
i  
li ti   
[ 7] 
 J /J ⇧  
Acute-chronic 
i fectio  
Glatiramer acetate** No effect 
i  
li ti   
[ 9] 
DA SJL/J ⇧** 
Chronic 
inf ction 
Oral antibiotics** 
Not 
investigated 
Chr n c 
emyelin tio  ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-inf ction 
Antibody-mediated 
pletion 
(anti CD25) 
No effect No effect [146] 
Be n /  ⇩ -i f ti  
DT-mediated depletion 
in DEREG mice 
 ff t  ff t [ 50] 
DA C57BL/6 ⇧ Pre-infection 
Ado tive ransfer of ex 
vivo g nerat d iTreg 
o effect o effect [147] 
 /  ⇧ -i f ti  Expansion by IL-2C No effect No effect [ ] 
BeA  C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infecti n 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chr nic 
de yeli at o  ⇩
[151] 
⇧ I crease or ⇩ decr ase of r gulatory T cell (Treg) umbers, vir l load, or isease.  Tim  of Treg 
manipulation refers to the disease phase (p -infectio : befor  or at the day of intracranial infection;
ac te infection: 1–2 weeks p st fection; chronic infection: 3–4 w eks post infection). ** Indirect effect
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 backgro n ); GITR: 
glucocorticoid-induced tumor necrosis factor-rec pto  (TNFR)-related pr tein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detr mental effec s of Treg on antiviral mmunity depe d on th  genetic
backgro d of the a imal, timing of ma ipulation, and th  integrity of cyt toxic respons s (Table 3).
The mechanisms, by which Treg exert their suppressive unction in early TMEV-infecti n of SJL mice,
remain uncertain. One of the most potent effecto s s creted by Treg s IL-10, and elevated l vels of
the cytokine have been detected in brains of acutely infecte  SJL mic  compared to lower levels in
C57BL/6 mice [145]. In TMEV-infected SJL mice tr ated with antibodies blocking the IL-10 receptor,
no positive effect on viral l ad in the brain or the spinal cord was observed during acute or chronic
infectio  [152,153]. H wever, IL-10 blockade resulted in incr ased hippocampal damage during acute
infection, which s u ually only minim l or absent in SJL mic  [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most lik ly medi ted by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Pre-infection Expansi n by IL-2C No effect No effect [151]
BeAn C57BL/6 Treg
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s muri e 
encephalomyelitis virus infecti n. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Ma ipulation
* 
M thod Viral Load Dis ase 
Refer
ence 
Be n SJL/J  r -i f ti  
A tibody–mediated 
(anti-CD25 r -GITR) 
⇩ 
Del y d chronic
demyelination 
[ 6] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo gen rated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
inf ction 
Adoptive transfer of ex 
vivo g n rated iTr g 
No effect 
Chronic 
demyelin tio  ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acet te** No ffect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demy lination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-i fection 
Antibody-m iated 
depletion 
anti CD25) 
No effect No effect [146] 
Be n C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Ad tive t an fer of x
vivo ge er t  iTr g 
No effect No effe t [147] 
B An C57BL/6 ⇧ Pre-infect on Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelin tio  ⇩ 
[151] 
⇧ Increase r ⇩ decr ase of regulat ry T cell (Tr g) numbers, vir l load, or dis ase. * Time f Tr g 
manip lation ref rs to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect ffect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodi ; iTreg: ind ced Tr g. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only inimal r absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
and
CD8
 
Table 3. Effects of regulatory T cell m ipulati n on viral l ad and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Tim  of Treg 
Manipulation
* 
Method Viral Load D sease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
d pleti n 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pr -i tion 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute isease ⇧ [147]
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transf r of ex 
vivo generated iTreg 
N  ffect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
i f ti  
Glatiram r acetate** No effect 
Chronic 
de yelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
i fectio  
O al antibiotics** 
Not 
investigated
Chr nic 
demyelinatio  ⇩ 
[148] 
eAn C57BL/6 ⇩ Pre-infe tion 
Antibody-m diated 
depletion 
(anti CD25) 
No effect N  effect [146] 
BeAn C57BL/6  Pre-infection 
DT-mediated pletion 
in DEREG mice 
No ef ct No effect [150] 
DA C57BL/6 ⇧ Pre-infectio  
Adoptive transfer of ex 
viv  gener ted iT eg 
N  effect No eff ct [147] 
BeAn C57BL/6 ⇧ Pre-i tio  Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-inf ction 
Expansion by IL-2C, 
a tibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelinatio  ⇩ 
[151] 
⇧ I crease or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, r disease. * Time of Treg
manipulation refers to th  disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regul tory T cell ice (C57BL/6 background); GITR: 
glucoc rticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interl ukin (IL)
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
I summary, detrimental effects of Treg o  an iviral immunity depend on th  genetic 
background of the animal, timing of ma ipulatio , and the integrity of cytotox c sponses (Table 3). 
The mecha isms, by hich Treg exert their s ppressive fun  in ea ly TMEV-infection of SJL mice, 
r mai  uncertain. One of th ost potent effectors s cr ted by Treg i  I - , and elevated levels of 
th  cytokine have be n d tected i  bra s of acutely infected SJL mic  compared to lower l vels in 
C57BL/6 ice [145]. In TMEV-inf cted SJL mice treated with antibod es blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Pre-infection
Expansion by IL-2C,
antibody-mediated
CD8-depletion
 
Table 3. Effects of regulatory T cell manipulation on viral load d disease in Th il r’s murine 
encephal myelitis virus inf ction. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Ref r
ence 
BeAn SJL/J ⇩ Pre-inf ction 
Antibody–mediated 
depletion 
( -CD25 or -GITR) 
⇩ 
Delayed chronic 
demyeli ation 
[146] 
DA SJL/J ⇧ Pr -infe tion 
Adoptive transfer of ex 
vivo ge rated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Ad ptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
i f ction
Glatiram r acetate** No effect 
Ch nic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
B A  C57BL/6 ⇩ P -infecti n 
Antibody-medi d 
depletion 
(a ti CD25) 
No ffect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT- ediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-i fection 
Adoptive transfer of ex 
vivo g nerated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
P -i fection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation fers to the dis ase phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Ab reviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor ecrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes co sisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
I  summary, detrime tal effects of Tr g on antiviral immunity depend on the genetic 
background of th  animal, tim ng of manipulation, a d the integrity of cytotoxic responses (Table 3). 
The mechani s, by which Treg exert th ir suppressive function in early TMEV-infection of SJL mice, 
r m in uncertain. One of the ost po e t effec ors secreted by Treg is IL-10, and elevated levels of 
the cytoki e have be n ete ted n brains of a utely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mic treated with antibodies blocking the IL-10 receptor, 
no positive ef ect on viral lo d in the brain or the spinal cord was observed during acute or chronic 
infection [152 153]. However, IL-10 blockade re ulted in increased hippocampal damage during acute 
inf ction, which is usua ly o ly minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiv ral immun ty is most likely m diated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Chronic
demyelination
 
Table 3. Effects f regulatory T cell mani ulati n n viral load and disease in Theiler’s murine 
encephalomyelitis virus infecti . 
Virus 
Strai  
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Ma ipulation
* 
Method Viral Lo d Disease 
Refer
ence 
BeAn SJL/J  Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
 SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
i fection 
Adoptive transfer of ex 
vivo generated iTr g 
No effect 
Chronic 
demyelination ⇩ 
[147] 
D  SJL/J ⇧** 
Acut -chronic 
infection 
Glatiramer acet te**
Chronic 
demyelination ⇩ 
49
D  SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
48
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediat d 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-i fection 
DT-m diated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-inf ction Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
a d 
CD8⇩ 
Pre-i fection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ I crease or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
ma ipulat on r fers to th  diseas  ph se (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 w eks post inf ct on; chronic infection: 3–4 weeks pos  infection). ** Indirect effect 
n Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glu ocorticoid-induc d t m r necrosis factor-receptor (TNFR)-relat d prot in; IL2C: interleukin (IL) 
2 immune c mpl xes onsisting of recombinant IL-2 and anti-IL-2-antib dies; iTreg: nduced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[151]
 
Table 3. Effects of regulatory T cell manipulation on viral load and dis ase in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chr nic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acut  d se se ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelinati n ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatir mer acetat ** No effect 
Chronic 
emyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
O al antibiotics** 
N t 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infecti n 
Anti ody-mediated 
depletion 
( nti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated d pletion 
in DEREG ice 
No effect No effec  [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transf r ex 
vivo ge rated iTr g 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansi  by IL-2C No ffect No ffect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediat d 
CD8-depletion 
⇧ 
Chronic 
demy l nat on ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or di e s . * Time of Treg 
manipulation refers to the disease hase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic inf ction: 3–4 w eks post infectio ). ** Indirect ffect
on Treg. Abbreviations: DEREG: depl tion of regulatory T cell mice (C57BL/6 backgrou d); GITR: 
glucocorticoid-induced tumor necrosis factor- eceptor (TNFR)-related prot in; IL2C: nterleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg  antiviral immunity de end on the genetic 
background of the animal, timing of manipulation, and th  integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert thei  suppressiv function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Increas or
 
Table 3. Effects of regulatory T cell manipulation on vir l load a d disease in The l r’s ur e 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
M thod Viral Lo d Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antib dy–mediated 
depl tion 
(an i-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection
Adoptive transfer of ex 
vivo gen rated iTreg 
⇧ Acut  isease ⇧ [147]
DA SJL/J ⇧ 
Chronic 
infection
Adop ive transfer of ex 
vivo generated iTreg 
No effect 
Chroni  
demyelin tion ⇩ 
[147]
DA SJL/J ⇧** 
Acute- hronic 
infection
Gl tiramer acetate** No effect 
Chron
demy lin tio ⇩
[149]
DA SJL/J ⇧** 
Chronic 
infecti n 
Oral ntibiotics** 
Not 
i vestigat d 
Chroni  
demyelin tion ⇩ 
[148] 
BeAn C57BL/6 ⇩ P e-i fection 
Antibody-mediated 
depletion 
(anti CD25) 
No ffect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infectio  
DT-mediated depletion 
in DEREG mice 
No eff ct No ef ect [150] 
DA C57BL/6 ⇧ Pr -infec on 
Adoptive transfer of ex 
vivo generated iTreg 
No effect N  ffect [147] 
BeAn C57BL/6 ⇧ Pr -infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infe tion 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Tr g 
manipulation refers to the d sease phase (pre-infection: before or at the day of intracranial i fection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: d pleti n of regulatory T cell mic  (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
decr ase of r gulato y T ell (Tr g) umbers, v ral load, or dise se. * Time of Treg ma ipulation refers to
the disease phas (pre-i f c : befor or at the d y f intracranial infection; acute infection: 1–2 weeks post infection;
chronic infection: 3–4 we ks post i fec ion). ** Indir ct effect o Treg. Abbreviations: DEREG: depletion of regulatory
T cell mice (C57BL/6 background); GITR: glu ocorticoid-induced tumor necrosis factor-receptor (TNFR)-related
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i duce neu ologic d sease in susceptible st ains of ice. Extremely virulent strains (e.g., JHM) cause
acute encephal tis, whereas mor atte ated st ai s (e.g., A59, J2.2v-1) are us d to stu y acute dis ase
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Following infection with neurovirulent JHM strain of MHV, insufficient Treg responses with
dominant virus-specific CD4+ responses correlated with acute fatal encephalitis of mice. Treg seem to
be critical for disease attenuation, as Treg transfer protects from fatal encephalitis following infection
with highly neurovirulent strains. Moreover, Treg depletion prior to infection increased the mortality
in mice infected with attenuated MHV JHM mutant, which usually results in non-lethal infection [154].
Similarly, Treg-depletion prior to acute infection with the attenuated MHV strain A59 led to increased
numbers of apoptotic neurons in the brain but did not affect the CNS recruitment of virus-specific
CD8+ and CD4+ T cells [155]. The studies indicates that in acute MHV encephalitis, Treg may help to
limit immunopathology without inhibiting antiviral immunity [154,155]. Using tetramer techniques,
virus-specific Treg populations expressing IL-10 and IFN-γ have been found in the CNS of mice infected
with neuroattenuated MHV. These cells are thought to be thymus-derived natural Treg based on
expression of the Helios transcription factor. They showed an activated state at the site of inflammation
with high expression levels of CD69, ICOS, and CTLA-4, and had the ability to suppress MHV-specific
effector T cells [70]. Using the neuroattenuated MHV strain (rJ2.2), virus-specific Treg have been
shown to inhibit effector T cell expansion in lymph nodes and migration of pathogenic CD4+ T cells
to the CNS. Adoptive transfer of MHV-specific Treg enhanced the survival rate of infected mice by
reducing the frequencies of pathogenic CD4+ T cells and microglial responses in the brain in acute
encephalitis [156].
A beneficial role of Treg has also been observed in chronic demyelinating disease caused by
infection with attenuated MHV strains, although some differences have been observed depending on
the time of Treg manipulation. Functional Treg inactivation by CD25-treatment prior to acute infection
with neuroattenuated MHV strain increased demyelination during viral persistence, indicating that
immunopathological processes resulting in myelin destruction are initiated at early stages and that
they can be attenuated by Treg [157]. Moreover, the adoptive transfer of naïve Treg after initial
effector T cell priming following infection with neuroattenuated MHV significantly reduced spinal
cord demyelination and inflammation, as well as improving motor coordination deficits. Strikingly,
transferred Treg did not compromise viral clearance or alter the percentage of virus-specific cells
in the CNS of infected mice, showing a beneficial role of Treg also at a time when CNS infection
has already been established. Transfer of Treg concomitant with MHV-specific T cells to infected
recombination-activating gene (RAG)-deficient mice suggested that Treg reduce the migration of
pathogenic CD4+ T cells to the brain by inhibiting the antigen presenting capacity of dendritic
cells and pro-inflammatory cytokine and chemokine expression in the CNS-draining lymph nodes
in MHV-infected mice [158,159]. In addition, Treg have been shown to inhibit the migration of
myelin-specific T cells to the brain. The reduced CNS homing might be caused by Treg-mediated
downregulation of CXCR3 expression on activated T cells in secondary lymphoid organs. The results
indicated that Treg mainly attenuate autoreactive T cells during acute MHV infection but leave
protective antiviral immunity intact [155].
By contrast, during persistent MHV infection, Treg seemto control myelin-specific T cell responses
primarily in lymphoid organs but do not prevent autoimmune pathology in the CNS. Hence,
Foxp3-ablation during the chronic phase does not affect inflammation, virus load, and autoimmune
demyelination in the CNS. The disease phase-dependent effects of Treg-depletion with T cell retention
in lymph nodes may be attributed to reduced effector T cell trafficking probably due to restored
blood–brain barrier permeability in chronic infection. As observed in IL-27 receptor-deficient mice,
IL-10-producing Tr1 cells infiltrated the CNS during chronic MHV infection and were critical for
preventing autoimmunity and myelin loss at the site of persistent infection [160].
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Table 4. Effects of regulatory T cell manipulation on viral load and disease severity in acute and chronic
infection with neurotropic mouse hepatitis virus.
Virus Strain Mouse Strain Treg
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delay d chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Gla iramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
inv stigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of anipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Time of Treg
Manipulation* Method Viral Load
Disease
Severity Reference
Effects on acute encephalitis
A59 (low
virulence) C57BL/6
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
ot 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG ice 
No effect No effect [150] 
DA C57BL/6  Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell ice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ I crease or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
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Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infectio . 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Ma ipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
D  SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
D  SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
o effect 
Chronic 
de yelination ⇩ 
[147] 
D  SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
de yelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
Be n C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
o effect o effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
Be n C57BL/6 ⇧ Pre-infection Expansion by IL-2C No eff ct No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyeli ation ⇩ 
[ 51] 
⇧ Incre se or ⇩ decrease of regulato y T cell (Treg) numbers, viral load, or disease. * Ti e of Treg 
ma ipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-in uced tu or necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisti recombin nt IL-2 and ant -IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic respons s (Table 3). 
The mechanis s, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated level  of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
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nc phalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
B An SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
o effect o effect [147] 
BeA  C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease.  Time of Treg 
manipulation refers to the disease phase (pre-infection: befor  or at the day of intracranial infection;
ac te infection: 1–2 weeks p st infection; chronic infection: 3–4 w eks post infection). ** Indirect effect
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 backgro n ); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detr mental effec s of Treg on antiviral mmunity depe d on the genetic
backgro d of the a imal, timing of ma ipulation, and th  integrity of cytotoxic respons s (Table 3).
The mechanisms, by which Treg exert their suppressive unction in early TMEV-infecti n of SJL mice,
r main u certain. One of the most potent effecto s s creted by Treg s IL-10, and elevated l vels of
the cytoki e have b en detected in brains of acutely infecte  SJL mic  compared to lower levels in
C57BL/6 mice [145]. In TMEV-infected SJL mice tr ated with antibodies blocking the IL-10 receptor,
no positi e effect on viral l ad in the brain or the spinal cord was observed during acute or chronic
infectio  [152,153]. H wever, IL-10 blockade resulted in incr ased hippocampal damage during acute
infection, which s u ually only minim l or absent in SJL mic  [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most lik ly medi ted by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
mortality
 
Tabl  3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis vi us infection. 
Virus 
Strain 
Mous  
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibo y–mediated 
depleti n
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre infection 
Adoptiv  transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
B An C57BL/6 ⇩ Pre-infection 
Antibo y-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ I crease or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post inf ction). ** Indir ct effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncerta n. On  of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neu oprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[154]
rJ (high virulence) C57BL/6
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infecti n. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or  
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-i fecti  
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed hronic 
demyelination 
[146] 
DA SJL/J ⇧ Pr -infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chro ic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
Chr nic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No ff ct 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
i fecti  
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(anti CD25) 
No ffect No ffect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediate  depletion 
in DEREG mice 
No effect No effect [150] 
D  /   -i f ti  
Adoptive transfer of ex 
vivo g nerated iTreg 
 ff t  ff t [ 47] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effe t [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-i tion 
Expansion by IL-2C, 
a t body-mediated 
CD8-depletion 
⇧ 
Chronic 
demyeli ation ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 backgr ); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: i terleukin (IL) 
2 immune complexes consisting of recombi ant IL-2 and anti-IL-2-antibodies; iTreg: i d ce Treg. 
In summary, detrimental effects of Treg on an iviral immunity depend on th  genetic 
background of the animal, timing of ma ipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by hich Treg exert their suppressive function in early TMEV-infection of SJL mice, 
r mai  uncertain. One of the ost potent effectors secreted by Treg i  I - , and elevated levels of 
th  cytokine have be n d tected i  brai s of acutely infected SJL mic  compared to lower l vels in 
C57BL/6 ice [145]. In TMEV-inf cted SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Acute infect on Adoptive transf r ofbulk Treg No effect
Encephalitis
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
 SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
 SJL/J ⇧
hronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
hronic 
de yelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
e n 57 /6 ⇩ re-infection 
Antibody-mediated 
depletion 
(anti CD25) 
o effect o effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in EREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo gen rated iTreg 
No effect No effect [147] 
BeA  C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyeli ation ⇩ 
[151] 
⇧ I r ase or ⇩ de rease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refer  t  the disease phase (pre-infection: before or at the day of intracranial inf ction; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 im une complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral i munity depend on the genetic 
backgrou d of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
rem in uncertai . One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytok ne have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infecti n, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
mortality
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
M use 
S rain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pr -i fecti  
ntibo y–mediated 
depleti n
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
 SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
 SJL/J ⇧ 
hronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect 
hronic 
de yelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
ntibo y-mediated 
depletion 
(a ti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive t ansfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
hronic 
demyeli ation ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manip lation refers to the disease phase (pre-infection: before or at the da  of intracranial infection; 
acute i f ction: 1–2 weeks post infecti n; chronic infection: 3–4 weeks post infecti n). ** Indirect effect 
on Treg. Abbr viations: DEREG: depletion of regulatory T c ll mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor ecrosis factor-re eptor (TNFR)-rela ed protein; IL2C: int rleukin (IL) 
2 immun  complex s consisting of r combinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of th  animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
rema  un ertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokin  have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. I  TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positiv  effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[154]
rJ.2.2 (low
virulence) C57BL/6
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infecti n. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyeli ation 
[146] 
D  SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
D  SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
o effect 
Chronic 
de yelination ⇩ 
[147] 
D  SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acet t ** No effect 
Chronic 
de yelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-mediated 
depletion 
(a ti CD25) 
No effect No effect [146] 
 /  ⇩ r -i f ti  
DT-mediated depletion 
in DEREG mice 
 ff t  ff t [ 0] 
D  /   -i f ti  
Adoptive transfer of ex 
vivo generated iTreg 
 ff t  ff t [ 47] 
Be n C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effe t [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelinati n ⇩ 
[151] 
⇧ I crease or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Ti e of Treg 
manipulation refers to th  disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks p st infection; chronic inf tion: 3–4 weeks post infection). ** Indirect ff ct
n Treg. Abbr viations: DEREG: depletion of r gulatory T cell mice (C57BL/6 background); GITR:
gluco orticoid-i uced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisti recombin nt IL-2 nd ant -IL-2-antibodies; iTreg: ind ced Treg. 
In summary, detrimental effects of Treg on antiviral im i y d pend on the genetic 
background of the animal, timi g of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg xert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected i  brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 recep r, 
no positive effect on viral load in the brain or the spinal cord was observed dur ng acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Pre-infection
Adoptive transf r of
bulk or virus-specific
Treg
No effect Encephalitis
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theil r’s murine 
encephalomyelitis virus inf ction. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
Be n SJ /J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
D  SJL/J ⇧
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTreg 
o effect 
Chronic 
de yelination ⇩ 
[147] 
D  SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
de yelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
⇩ 
Antibody-mediated 
depletion 
(anti CD25) 
No effect No effect 46
Be n C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
o effect o effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effec No effect [147] 
Be n C57BL/6 ⇧ Pre-inf ction Expansion by IL-2C No ffect No effect [151] 
BeA  C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbe s, viral load, or isease. * Time of Tr g 
manipulation ref rs to the disease phase (pre-infection: b fore or at the day of intracranial infection; 
acu e i fection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-in uced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 im une complexes consisti recombin nt IL-2 and ant -IL-2-antibodies; iTreg: induced Treg. 
In summary, detrim ntal effects of Treg on antiviral immunity depend on the netic
backg ound of the ani al, timing of nipulation, and th  integ ity of cytotoxic responses (T ble 3).
The m chanisms, by which Treg exert the r suppressive fu ction in early TMEV-infection of SJL mice,
rem n uncertai . One f he most potent effectors secret d by Treg is IL-10, and elevated levels of 
the cytok ne have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
mortality
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
nceph lomyelitis virus infection. 
Virus 
Strain 
M use 
S rain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulati
* 
Method Viral Load Disease 
Refer
ence 
Be n SJ /J ⇩ Pre-i fecti  
Antibo y–mediated 
depleti n
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
D  SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo generated iTr g 
o effect 
Chronic 
de yelination ⇩ 
[147] 
D  SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
de yelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chroni  
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibo y-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
Be n C57BL/6 ⇩ Pre-infection 
D -mediated depletion 
in DEREG mice 
o effect o effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
Be n C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion
⇧ 
Chronic 
demyelinatio  ⇩ 
[151] 
⇧ Increa  or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbrevia ions: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-i uced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immun  compl xes consisti recombin nt IL-2 and ant -IL-2-antibodies; iTreg: induced Treg. 
In summary, detrim ntal effects of Treg on antiviral immunity depend on the enetic
background of th animal, timing of nipulation, and the integrity of cytotoxic responses (T ble 3).
The m chanisms, by which Treg exert the r suppressive fu ction in early TMEV-infection of SJL mice,
rema  un ertain. One f he most potent effectors secret d by Treg is IL-10, and elevated levels of 
the cytokin  have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 mice [145]. I  TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positiv  effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[156]
Eff cts on chronic de yelinating diseas
J2.2v-1 (low
vi ulence) C57BL/6
 
Table 3. Effects of regulatory T cell man ulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time f Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–medi ted 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Dela d chr ic 
demyeli ation 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTreg 
⇧ Acute dis ase ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
i fectio  
Adoptive transfer of ex 
vivo ge erated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
i fectio  
Glatiramer acetate** No effect 
Chroni  
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infectio  
Oral antibiotics** 
Not 
inv stigated 
Chroni  
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
Antibody-me iated 
depletion 
(anti CD25) 
No effect No effe t [146] 
e  57 /6 ⇩ re-i fecti  
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
viv  generated iTreg 
No effect No effe t [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Exp sion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase o  ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or dis as . * Time of Treg 
manipulation refers to the disease ph se (pre-infection: before or at the da  f intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 backgrou d); GITR: 
glucocorti oid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune com lexes consisting of recombinant IL-2 and a ti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrime tal effects f Tr g on antiviral immunity depend on t e genetic
background of the animal, timing of man pulation, and the integrity of cytotoxic respon es (Table 3). 
The mechanisms, by which Tr g exert their suppressive function in early TMEV-infection o  SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detect d in br ins of acutely infected SJL mice compared to lower level  in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Pre-inf ction
-acut infect on
Antibody–media ed
depletion (anti- D25) No effect Demyelination
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
ncephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load D sease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generated iTr g 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infecti  
Adoptiv  transfer of ex 
vivo generated iTreg 
No effect 
Chronic 
demyeli ation ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** No effect 
Chronic 
demyeli ation ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre-infection 
A tibo y-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-me i t  depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptiv  transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeA  C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antib dy-me iated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ In r ase or ⇩ e reas  of regulatory T cell (Tr g) numbers, v ral load, r disease. * Time of Treg 
manipulation refers t  the disease ph se (p -inf ction: b fo  or t the ay f intracranial i fection; 
acute in ection: 1–2 w eks post inf ction; ch onic infection: 3–4 eeks post infection). ** In irect effect 
n Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 backgroun ); GITR: 
glucocorticoid-induced tumor necrosis factor-rece tor (TNFR)-related prot in; IL2C: interleukin (IL) 
2 immu  c mpl xes co sisting of recombinant IL-2 and anti-IL-2-antibodies; iTr g: ind ced Tre . 
In summary, detrimental effects o  Treg on antiviral immunity depend on the genetic 
background of th  a imal, iming of manipulation, and the integrity of cytotoxic responses (Table 3). 
The m chanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in br ins of acutely infected SJL mi e compared to lower levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed d ring acute or hronic 
infection [152,153]. H wever, IL-10 blockade resulted in increased hippocampal damage during acute 
infecti n, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotectiv  echanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[157]
J2.2v-1, rJ2.2 (low
virulence) C57BL/6RAG1
-/-
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus inf ti . 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease
Refer
ence
BeAn SJL/J ⇩ Pre-infection 
Antibody–medi ted 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Dela d chr ic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptiv  transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
D  SJL/J ⇧
Chronic 
infection 
Adoptive ransfer of ex
vivo generated Treg 
Chronic 
demyelination ⇩ 
47
SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** 
Chroni  
demyelination ⇩ 
9
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiot cs** 
Not 
investigated 
Chroni  
d myelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pr -infection 
A ti - i t  
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of ex 
vivo enerated iTreg 
No effect No effect [147] 
BeAn C57BL/6 ⇧ Pr -infect on Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depl tion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decre se of re ulatory T cell (Treg) umb rs, viral load, or disease. * Time of Tr g 
manipulation refers to the diseas  phase (pre-inf ction: before or at the day of i tra ra ial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infect on). ** I direct ffect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 backgr und); GITR: 
glucocorticoid-induced tumor ne rosis factor-r ceptor (TNFR)-related protein; IL2C: int rleukin (IL) 
2 immune complexes consisting of recombinant IL-2 a d anti-IL-2-antibodies; i r g: induced Treg. 
In summary, detrime tal effects f Tr g on antiviral immunity depend on the genetic
background of the animal, timing of man pulation, and the integrity of cytot xic respon es (Table 3). 
The mechanisms, by which Tr g exert their suppressive function in early TMEV-infection of SJL mic , 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of
the cytokine have been detect d in br ins of acutely infected SJL mice compa d to low r levels in 
C57BL/6 mice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Acute infection Adoptive transfer ofbulk Treg No effect D myelination
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
enc phalomyelitis virus inf ti .
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
M hod Viral Load D sease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delay d chronic 
demyelination 
[146] 
 SJL/J ⇧ Pre-infection 
Ad ptiv  transfer of ex 
vivo generated iTreg 
⇧ Acute disease ⇧ [147] 
 SJL/J ⇧ 
hronic 
infection 
Adoptiv  transfer of ex 
vivo generated iTreg 
No effect 
hronic 
de yelination ⇩ 
[147] 
DA SJL/J ⇧**
Acute-chronic 
infection 
Gl tiramer acetate** No effect 
Chronic 
demyeli ation ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chronic
demyelination ⇩ 
[148] 
BeA  C57BL/6 ⇩ Pre-infection 
A tibody-mediated 
depletion 
(anti CD25) 
No effect No effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-me iat d depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptiv  transfer of ex 
vivo generated iTreg 
No effect No effect [147] 
BeA  C57BL/6 ⇧ Pre-infection Expansion by IL-2C No effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Ex ansion by IL-2C, 
antibody-mediate  
CD8-depletion 
⇧ 
Chronic 
demyeli ation ⇩ 
[151] 
⇧ Inc as  or ⇩ de rease of regulatory T cell (Treg) numbers, viral load, or isease. * Time of Treg 
nipulation refers to the disease phase (pre-infectio : b fore or at the day of intracra ial infection; 
acute infection: 1–2 w eks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tumor necrosis factor-rece tor (TNFR)-related prot in; IL2C: interleukin (IL) 
2 immune c mplexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: ind ced Tre . 
In summary, d trimental effects of Treg on antiviral immunity epend on the genetic 
ba kground of th  animal, timing of manipulation, a d the integrity of cytotoxic responses (Table 3). 
The mechan sms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. On of the most potent effectors secreted by Treg is I -10, and el vat d levels of 
the cytoki e have been detected in brains of acutely inf ct d SJL mice compared to lower levels in 
C57BL/6 ice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no posi ve effect o  viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
[159]
J2.2v-1 (low
virulence) C57BL/6
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strai  
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Tim  of Treg 
Ma ipulation
* 
Method Viral Load Disease 
Refer
ence 
e  SJL/J  re-i fectio  
Antibody–mediated 
d pletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
 J /J ⇧ Pre-infection 
Adopt ve transfer of ex 
viv  generated iTreg 
⇧ Acute d sease ⇧ [ 7] 
 J /J ⇧ 
r ic 
i fecti  
Ado tive transfer of ex 
vivo ge erated iTreg 
No effect 
r i  
e eli ti   
[ 7] 
D  SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate** o effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
i fection 
Oral antibio cs** 
Not 
investigated 
Chronic 
demy linati  ⇩ 
[148] 
Be n 57BL/6 ⇩ Pre-infection 
Antibody-m diated 
deple  
(anti CD25) 
o effect o effect [146] 
BeAn C57BL/6 ⇩ Pre-infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer of x 
vivo g n ra d i reg 
No effect No eff ct [147] 
B An C57BL/6 ⇧ Pr -inf tion Exp nsion by IL-2C N  effect No effect [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-infection 
Expansi n by IL-2C, 
antibody-mediat d 
CD8-depleti n 
⇧ 
Chr nic 
demyelinat on ⇩ 
[151] 
⇧ Incr ase or ⇩ decrease of regulatory T cell (Treg) numbers, vir l l ad, or is ase. * Time of Treg 
ma ipulation refers to the disease phase (pre-infection: before or at the day of intracranial infection;
acute infe tion: 1–2 weeks post infection; chronic infectio : 3–4 weeks post nfection). ** Indir ct ff ct 
on Treg. Abbreviations: DEREG: deplet on of r gulatory T cell mice (C57BL/6 backgr u d); GITR: 
glucocorticoid-induced tumor nec osis factor-rec ptor (TNFR)-related protein; IL2C: interl ukin (IL) 
2 immune com lexes consisting of recombinant IL-2 and a ti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental ffects of Tr g on antiviral immunity depend on the g netic
background o  the anim , timing of man pula ion, and the integrity of cytotoxic respons s (Table 3).
Th  mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mic ,
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated lev ls of
the cytokine have been det cted in brains of acutely infect d SJL mic  compared to lower levels i
C57BL/6 ice [145]. In TMEV-infected SJL mice tr ated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. H wever, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
Transition from
acut to chronic
inf ction
DT-mediat d
depletion in DEREG
mice
Virus RNA
 
Table 3. Effects of r gulatory T cell manipulation on viral load and disease in Theiler’s murine 
encephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Meth d Viral Load Disease 
Refer
ence 
BeA  SJL/J ⇩ Pre-infection 
Antibody–mediated 
depl tion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive t a sfer of ex 
vivo g n rated iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
vivo g nerated iTreg 
No effect 
Chr nic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
i fection 
Glati amer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
i fection 
Oral antib otics** 
Not 
in stig t  
Chronic 
demyelination ⇩ 
[148] 
BeAn C57BL/6 ⇩ P -infection 
Antibody-m d ated 
depletion 
(anti CD25) 
No effect No effect [146] 
B An C57BL/6 ⇩ Pre-in ection 
DT-mediated depleti n 
in DEREG mice 
No effect No effect [150]
DA C57BL/6 ⇧ Pre-infection 
Adoptive transfer f ex 
vivo generated iTreg 
No ffect No eff ct [147] 
BeAn C57BL/6 ⇧ P e-infection Expansio  by IL-2C No eff N  ff ct [151] 
BeAn C57BL/6 
Treg⇧
a d 
CD8⇩ 
Pre-infection 
Expansion by IL-2C, 
antibody-mediated 
CD8-depletion 
⇧ 
Chronic 
demyelination ⇩ 
[151] 
⇧ Increase or ⇩ decrease of regulatory T cell (Treg) numbers, viral load, or disease. * Time of Treg 
manipulation refers to the disease ph se (pre-infection: before or at the d y of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of regulatory T cell mice (C57BL/6 background); GITR: 
glucocorticoid-induced tu or necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, d trimental effects of Treg on antivir l immunity d pend on the genetic 
background of the anim l, timing of manipulation, an  th  integrity of cytotoxic responses (Table 3). 
The mechanisms, by which Treg exert their suppr ssive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 ice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. However, IL-10 blockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
in
CLN, no effect
in CNS
No effect [160]
J2.2v-1 (low
virulence) C57BL/6
 
Table 3. Effects of regulatory T cell manipulation o  viral load and disease in Theiler’s murine 
e cephalomyelitis virus infection. 
Virus 
Strain 
Mouse 
Strain 
Treg 
⇩ or ⇧ 
Time of Treg 
Manipulati
* 
Method Viral Load Disea  
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 or -GITR) 
⇩ 
Delayed chronic 
e eli ti  
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptive transfer of ex 
vivo generate  iTreg 
⇧ Acute disease ⇧ [147] 
DA SJL/J ⇧ 
Chronic 
infection 
Adoptive transfer of ex 
viv  generated iTreg 
No effect 
Chronic 
demyelination ⇩ 
[147] 
DA SJL/J ⇧** 
Acute-chronic 
infection 
Glatir mer acetate** No effect 
Chronic 
demyelination ⇩ 
[149] 
DA SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chro ic 
demyeli ation ⇩ 
[148] 
BeAn C57BL/6 ⇩ Pre- nfection 
Antibody-mediated 
depletion 
(anti CD25) 
No eff ct No effect [146] 
BeAn C57BL/6 ⇩ Pre-infecti n 
DT-mediat d depletion 
i  DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre-inf ction
Adoptive transfer of ex 
vivo generated iTreg 
No effect No ffect [147] 
BeAn C57BL/6 ⇧ Pre inf cti n Expansion by IL-2C No effect No ff ct [151] 
BeAn C57BL/6 
Treg⇧ 
and 
CD8⇩ 
Pre-inf c ion
Expansi  by IL-2C, 
antibody-m diated
CD8-depletion
⇧ 
Chronic 
d my linati n ⇩ 
[151] 
⇧ Increase or ⇩ decr ase of regul tory T cell (Tr g) numbers, viral l ad, or disease. * Time of Tr g 
manipulatio  refers to the disease phase (pre-infection: before or at the day of intracranial infection; 
acute infection: 1–2 weeks post infection; chronic infection: 3–4 weeks post infection). ** Indirect effect 
on T eg. Abbreviations: DEREG: depleti of regulatory T cell mice (C57BL/6 background); GITR:
glucocorticoid-induced tumor necrosis factor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune complexes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity dep nd on the gene ic 
background o  the a imal, timing of manipulation, and the integrity of cytotoxic resp nses (Table 3). 
The mechanisms, by which Treg exert their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and el vated l vels f 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower l v ls in 
C57BL/6 mice [145]. In TMEV-infect  SJL mice reated with antibodies blocki g the IL-10 receptor, 
no positive effect on viral load in the brain or the spinal cord was observed during acute or chronic 
infection [152,153]. How ver, IL-10 b ockade resulted in increased hippocampal damage during acute 
infection, which is usually only minimal or absent in SJL mice [152]. Thus, IL-10 secretion apparently 
represents a neuroprotective mechanism in acute TMEV-infection, whereas the suppressive effect on 
antiviral immunity is most likely mediated by other Treg effector functions. 
4.2.2. Coronavirus Model of Demyelination 
**
Transition from
acute to chronic
infection
Stem cell transfer**,
antibody–mediat d
Treg e letion
(ant -CD25)
No effect Demyelination
 
Table 3. Effects of regulatory T cell manipulation on viral load and disease in Theiler’s murine 
e c phalomyelitis irus infection. 
Virus 
Strain 
Mouse 
Strain 
reg 
⇩ or ⇧ 
Time of Treg 
Manipulation
* 
Method Viral Load Disease 
Refer
ence 
BeAn SJL/J ⇩ Pre-infection 
Antibody–mediated 
depletion 
(anti-CD25 r -GITR) 
⇩ 
Delayed chronic 
demyelination 
[146] 
DA SJL/J ⇧ Pre-infection 
Adoptiv  transfer of ex 
vivo generat d iTreg
⇧ Acute disease ⇧ [147] 
D  SJL/J ⇧ 
Chronic 
infection 
Adoptive ransfer of ex 
vivo generated Tr g
  
Chronic 
demyelination ⇩ 
47  
 SJL/J ⇧** 
Acute-chronic 
infection 
Glatiramer acetate**   
Chro i  
demy lina ion ⇩ 
9  
D  SJL/J ⇧** 
Chronic 
infection 
Oral antibiotics** 
Not 
investigated 
Chroni  
demyelination ⇩ 
[ 48] 
BeAn C57BL/6 ⇩ Pre-infection 
A ti o - di t  
depletion 
(anti CD25) 
No effect No effect [146] 
BeA  C57BL/6 ⇩ Pr -infection 
DT-mediated depletion 
in DEREG mice 
No effect No effect [150] 
DA C57BL/6 ⇧ Pre- fection 
Adoptive transfer of x 
vivo generated iTreg 
No effe t No effect [147] 
BeAn C57BL/6 ⇧ Pre-infection Ex ansion by IL-2C No effect No effect [151] 
BeA  C57BL/6
Treg⇧ 
a d 
CD8⇩ 
Pre-i fectio  
Expansion by I -2C, 
ntibody-mediated 
CD8-depl ti n 
⇧ 
Chronic 
demy lination ⇩ 
[151] 
⇧ I crea e or ⇩ decr ase of regu atory T cell (Tr g) numbers, viral load, or dis ase. * Time of Tr g 
man pulation refers to the disease phase (pr -infection: before or at the day of intracranial infection; 
ac t  inf cti : 1–2 weeks pos  infectio ; chronic infection: 3–4 weeks post infectio ). ** Indirect effect 
on Treg. Abbreviations: DEREG: depletion of r gulatory T c ll mice (C57BL/6 b ckground); GITR: 
glucocorticoid-induced tumor necrosis f ctor-receptor (TNFR)-related protein; IL2C: interleukin (IL) 
2 immune compl xes consisting of recombinant IL-2 and anti-IL-2-antibodies; iTreg: induced Treg. 
In summary, detrimental effects of Treg on antiviral immunity depend on the genetic 
background of the animal, timing of manipulation, and the integrity of cytotoxic responses (Table 3). 
The mecha isms, by which Treg ex rt their suppressive function in early TMEV-infection of SJL mice, 
remain uncertain. One of the most potent effectors secreted by Treg is IL-10, and elevated levels of 
the cytokine have been detected in brains of acutely infected SJL mice compared to lower levels in 
C57BL/6 ice [145]. In TMEV-infected SJL mice treated with antibodies blocking the IL-10 receptor, 
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In raspi al tra splantation of neural prec rsor cells (NPC) derived fr m human e br onic ste
cells duced inal c rd i fla mation and d myelinati in MHV-infect d mice. Clinical recovery in
tran planted animals coinc ded with Treg infiltra i n i the spi al c rd [161]. Similarly, tra spla tati n
of embryoid b dy- iv d NPC t ans ntly i c eas Tr g numb rs i CNS-draining l mph nodes,
which correlat d with r myeli at on and reduced euroinflammation in MHV-inf cted ice [162].
Treg seem to b cr tical for white matter reg nera on in MHV nfection because antibody-me iated
T g- epl n i cr ases myeli l ss i tra splanted ice. Co-cul ure xperime t reveale that PC
increas d Treg prolif ration d induce onv ntion l cel s to diff entiate toward a Treg phenotype
in itro [161,162].
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resulting clinical dis as has been indep de tly de o strat in both mouse o els, indic ting that
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autoimmunity. Moreover, e results are fairly co sist nt, regardless of the used od l, virus strains, or
ethod of Treg manipulation. However, advers ffects on viral load hav bee observed in the TMEV
model. Here, suppression of antiviral im unity occurred i the acute disease phase, characterize by
high virus replication, whereas no effects are bserv in chronic, low-level viral replication. Moreover,
the effects were only observed in animals of a tain genetic background, which are highly pron
virus persistence by natu . TMEV infection has been performed in inbred mice i h oth r ge etic
backgrounds (e.g., Balb/c, C3H, DBA/1, 129), a d also recently in collaborative cross mice, resulting in
a broad rang of iseas phenotypes and susceptibility o virus persistence [143,163]. However, th
studies did ot investigate the impact of Treg manipulation on infection outcome. In the coronavirus
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been performed in animals of the same C57BL/6 background and negative effects of Treg on MHV
replication and persistence could occur in other mouse strains.
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5. Conclusions and Outlook
The evidence collected by immunophenotyping of human samples with neurotropic infections
suggests a connection between the magnitude and quality of Treg activity and the clinical outcome.
In addition, immunomodulatory approaches including Treg-enhancement strategies represent attractive
therapeutic methods for treating autoimmune neurologic diseases. Due to several limitations of studies
in human subjects, animal models of viral CNS diseases have been employed to elucidate the relevance
of certain immunophenotypes and their involvement in the pathogensis of infectious diseases. In the
described studies, positive and negative effects of Treg-manipulation have been delineated in rodents,
depending on the pathogen, infection route, disease phase, timing and method of intervention,
genetic background of the host, and integrity of other components of the immune response. Moreover,
the large body of data obtained in experimental settings clearly show multifaceted functions of the
Treg population, broadening the view of Treg as purely immunosuppressive cells.
Elevated Treg frequencies and/or activation levels in humans are suspected to suppress antiviral
immune responses and contribute to virus spread, CNS invasion, and establishment of virus persistence
or latency. Indeed, animal models of ocular, intranasal and cutaneous HSV infection and the TMEV
model for virus-induced demyelination confirmed the inhibitory effects of Treg on virus control.
Interestingly, findings in both models indicated that the impact of Treg enhancement or depletion
is highly dependent on the timing of the intervention. Although excessive Treg functions interfere
with virus elimination and local containment in very early phases of infection, Treg appear to have
negligible effects on virus control at later stages in these models. A similar situation is suspected
in flaviviral encephalitis, as elevated Treg responses pre-infection correlate with virus spread and
neuroinvasion, whereas high Treg numbers post-infection protect mice from fatal encephalitis.
In contrast to this, in mice infected with recombinant MV, the magnitude of Treg responses
significantly influenced viral load in the persistently infected brain. Apparently, the qualitative and
quantitative contribution of the Treg compartment to host defenses also depends on the infectious
agent. Hence, clinical application of Treg-enhancing strategies bears the risk of exacerbating persistent
or dormant infections or making the patient more susceptible to infections occurring in the course
of treatment. This risk could potentially be reduced by the use of antigen-specific Treg recognizing
self-epitopes, which are currently being developed [35].
In contrast to the mentioned findings, studies of experimental CNS neuroinfection have also
revealed that Treg can contribute to virus control, for instance, by eliminating infected macrophages,
as observed in the HIV-1 encephalitis model. Furthermore, the data generated in murine WNV
and MCMV infection clearly showed that Treg are substantially involved in the establishment of
tissue resident memory T cell populations in the CNS. Such antiviral functions of Treg have not been
investigated in the majority of infectious models.
An undoubtedly and clinically highly relevant beneficial effect of Treg infiltration into the infected
CNS is the suppression of excessive inflammatory responses and resulting protection of irreplaceable
neuronal populations. Treg-mediated neuroprotective effects have been demonstrated in mouse models
of retro-, herpes-, and flaviviral encephalitis. Treg-enhancing strategies further showed clear beneficial
effects in viral models of chronic demyelinating diseases. Interestingly, in many cases of persistent CNS
infections with low-level virus replication, elevated Treg levels did not seem to negatively influence
viral burdens, suggesting that Treg somehow are able to modulate detrimental inflammation while
ensuring sufficient virus control. The mode by which Treg can differentiate harmful and protective
immune reactions remains enigmatic. It has been recently proposed that epigenetic instability of the
Foxp3 locus could be a mechanism by which Treg differentiate between self- and non-self-antigens.
According to this theory, Treg equipped with high affinity T cell receptors (TCR) for foreign antigens
possibly occur due to the lack of negative selection in the thymus. Upon encounter of these antigens
in infection, the strong TCR signal combined with the effects of pro-inflammatory cytokines at the
infection site could destabilize Foxp3 expression, rendering Treg powerless or even converting them to
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effector T cells. Whether this phenomenon indeed occurs in vivo is still subject of debate because of
contradicting results obtained in different fate-mapping experiments [164].
Lastly, the findings summarized in this review also highlight the influence of genetic background on
immune system interactions. The best example is demonstrated in the TMEV model of demyelination,
as manipulation of the Treg compartment has produced markedly different results in mice on the
SJL and C57BL/6 background. The majority of animal experiments in the field of infectious diseases
are conducted in standard inbred mouse strains with well-characterized genetic and phenotypic
traits, resulting in predictable and reproducible results. However, these experiments do not allow
for a generalization of statements regarding the safety of immunomodulation because they are not
transferable to a population level. The development of collaborative cross (CC) mice facilitates the
extension of infection models to a broader genetic background while maintaining reproducibility.
It would be interesting to see how Treg manipulation influences disease outcomes in distinct CC strains.
However, specific targeting of Treg is currently only feasible in Foxp3DTR transgenic mice, which are
only available on inbred backgrounds.
An open question regarding Treg involved in the pathogenesis of viral CNS infection is their origin.
For a long time, it was assumed that peripheral Treg infiltrate neural tissues upon injury or disease.
Some animal experiments used adoptive transfer of GFP-labeled Treg isolated from the periphery of
donor mice, showing that Treg migrate from the periphery to the CNS upon neuroinflammation and
exert local effects (e.g., [93,105]). In other experiments, the origin of Treg present in the infected CNS
has not been investigated. Recently, distinct resident Treg populations have been described in various
tissues, including the CNS. These tissue Treg are currently gaining increasing attention for their unique,
site-specific properties and involvement in tissue regeneration [34,57,58].
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BDNF brain-derived neurotrophic factor
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CCL, CXCL chemokine ligand
CCN3 cellular network communication factor 3
CCR, CXCR chemokine receptor
CD cluster of differentiation
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CTLA-4 cytotoxic T-lymphocyte-associated Protein 4
DC dendritic cell
DEREG depletion of regulatory T cells
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GDNF glial cell line-derived neurotrophic factor
GFP green fluorescent protein
GITR glucocorticoid-induced TNFR-related protein
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HSV herpes simplex virus
ICOS inducible T cell costimulator
IDO-1 indoleamine 2,3-dioxygenase 1
IFN interferon
IgM immunglobulin M
IL interleukin
IL-2C IL-2-anti-IL-2-antibody complexes
iNOS inducible nitric oxide synthase
IPEX immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
iTreg induced regulatory T cell
JEV Japanese encephalitis virus
KLRG1 killer cell lectin-like receptor subfamily G member 1
LAG3 lymphocyte activation gene 3
MCMV murine cytomegalovirus encephalitis
MHC major histocompatibility complex
MHV mouse hepatitis virus
MS multiple sclerosis
MV measles virus
NMDA N-methyl-D-aspartate
NPC neural precursor cells
nTreg natural regulatory T cell
PD-L1 programmed death-ligand 1
RAG recombination-activating gene
SSPE subacute sclerotizing panencephalitis
STAT signal transducer and activator of transcription
Tconv conventional T cell
TCR T cell receptor
TGF transforming growth factor
TLR toll-like receptor
TMEV Theiler’s murine encephalomyelitis virus
TMEV-IDD Theiler’s murine encephalomyelitis virus-induced demyelinating disease
TNF tumor necrosis factor
TNFR tumor necrosis factor receptor
Tr1 type 1 regulatory T cell
Treg regulatory T cell
VZV Varizella-zoster virus
WNV West Nile virus
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